Best Grant Databases for Biomedical Researchers (2026)
Compare Grants.gov, NIH RePORTER, Instrumentl, Grantsights, and Candid for finding R01, R21, K awards, and foundation grants in 2026.
Senior Researcher, Oncology & Cell Biology
A senior researcher with 12+ years in oncology and cell biology, spanning tumor immunology, cancer metabolism, and translational oncology. Has served as a pre-submission reviewer for manuscripts targeting Nature Medicine, Journal of Clinical Oncology, Cancer Cell, and Cell Reports. Brings direct experience with desk rejection patterns, reviewer expectations at Cell Press, and the specific framing requirements for clinical oncology submissions. Published in Cancer Research, Oncogene, and Cell Reports.
Journals reviewed for:
Nature Medicine, Cancer Cell, Journal of Clinical Oncology, Cell Reports, Oncogene
Research published in:
Published in Cancer Research, Oncogene, Cell Reports, and JCO
Compare Grants.gov, NIH RePORTER, Instrumentl, Grantsights, and Candid for finding R01, R21, K awards, and foundation grants in 2026.
A model impact-factor page: not just the number, but what the metric means for fit, prestige, and realistic submission choice.
Manusights and Springer Nature Author Services solve different pre-submission problems: readiness diagnosis versus publisher-branded editing and author support.
A desk rejection risk review service checks whether your manuscript is likely to fail editorial screening before peer review.
Diabetes Care editors are screening for findings that change clinical practice, not just strong diabetes data. A strong cover letter makes the practice consequence obvious fast.
A model 'good journal' page: verdict first, then who should submit, who should avoid it, and what Cell Reports is actually good for.
BMJ charges ~$5,450 for open access. BMJ Open is $2,850 gold OA. Institutional deals, waivers for low-income countries, and full cost breakdown.
Frontiers in Plant Science charges CHF 2,950 for open access. Compare waivers, institutional discounts, and Plant Cell.
Frontiers in Microbiology charges CHF 2,950 for gold OA. Compare waivers, institutional deals, ASM, mBio, and ISME.
Advanced Energy Materials charges ~$5,500-$6,000 for open access. Wiley-VCH hybrid, IF ~26, DEAL coverage.
Blood charges $5,850 for open access and $85/page for ALL articles. Brief Reports cost $2,925. Full cost breakdown, waivers, and comparisons.
Construction and Building Materials charges $3,800-$4,200 for open access. Hybrid Elsevier model, free subscription route, and fit notes.
JACS charges $5,000-$6,000 for hybrid open access. Compare ACS deals, waivers, subscription route, and competitor costs.
Journal of Chemical Physics charges $2,500-$3,500 for open access. Compare AIP fees, waivers, PRB, CPL, and PCCP.
Nature Reviews Cancer charges $12,850 for open access. Compare invited-review fit, hybrid OA, deals, and peer journals.
NEJM charges ~$10,000 for open access. Compare subscription publishing, limited deals, compliance, and alternatives.
Physical Review B charges ~$2,100-$2,700 for open access. Compare APS page charges, SCOAP3 limits, and alternatives.
Physical Review D charges $2,100-$2,700 for open access. SCOAP3 covers most HEP articles for free. APS member discounts and funder compliance guide.
STOTEN charges ~$4,200 for open access. Compare Elsevier coverage, waivers, and fit with ES&T or Water Research.
Small charges ~$5,000-$5,500 for open access. Compare Wiley DEAL coverage, waivers, ACS Nano, Nano Letters, and Nanoscale.
A practical Cell submission process guide covering what happens after upload, what editors screen for first, and what to fix before you submit.
How to write a point-by-point response to reviewers for Cancer Letters, where a major revision means functional and in vivo validation, not a descriptive rewrite. Grounded in pre-submission review work on Cancer Letters manuscripts.
How to write a point-by-point response to reviewers for Clinical Cancer Research, where the translational-relevance bar carries into revision, biomarker claims need a validation cohort, and preclinical answers to a clinical-bridge request fail.
How to write a point-by-point response to reviewers for Current Biology, where Cell Press editors scope which reviewer demands are mandatory and a major revision usually means new experiments plus a sharper broad-biology story.
A pre-submission readiness check for Cancer Letters: the mechanism-shown-not-inferred bar the desk applies, the functional and in vivo validation editors expect, and a clear submit-or-wait verdict before you submit.
How to write a point-by-point response to reviewers for The Lancet Oncology, where a separate statistical reviewer runs in parallel with clinical referees and the revision bar is re-analysis, not rewording.
Rejected from Cancer Research? 7 alternative cancer journals by fit, scope, and review speed, plus the AACR Manuscript Transfer route.
Rejected from Cell Death and Differentiation? 7 alternative journals by fit, scope, review speed, and APC, plus the Nature transfer route.
Rejected from Clinical Cancer Research? 7 alternative oncology journals by fit, scope, and review speed, plus the AACR transfer route.
A practical JECCR submission guide for authors deciding whether the manuscript has the translational cancer relevance, mechanistic depth, and package discipline this journal screens for.
PLOS ONE does not evaluate novelty or significance. It evaluates scientific soundness. A strong cover letter proves methodological rigor instead of overselling impact.
Pre-submission guide for JACS covering scope expectations for Communications vs Articles, broad-appeal requirements, and comparison with Angewandte Chemie.
Molecules (MDPI) publishes 5,000+ chemistry papers yearly with an IF of ~4.6 and 35-45% acceptance rate. This guide covers scope, APC, review speed, and the MDPI reputation question.
Nature Methods is commonly estimated to accept about 8-10% of submissions and desk-rejects 70-75%. This guide covers the methodological innovation bar, benchmarking requirements, and how it differs from Nature Biotechnology.
Neuron is commonly estimated to accept about 10-12% of submissions and desk-rejects 70-75%. This guide covers what Cell Press neuroscience editors want, from circuit-to-behavior depth to mechanistic completeness.
Nature editors are screening for broad scientific consequence, not just excellent discipline-specific work. A strong cover letter makes that flagship case obvious fast.
A practical Nature Reviews Cancer process guide covering what happens after a pitch, what editors judge first, and how to read silence or delay.
A practical JCO submission process guide covering what happens after upload, what editors screen first, and where papers lose momentum.
A practical Journal of Clinical Oncology submission guide: what fits, what editors screen for, and how to tell whether your paper is ready.
A practical Annals of Oncology submission guide covering package readiness, editorial priority signals, and what to fix before upload.
Editage is a legitimate service backed by Springer Nature. Whether it's worth the investment depends entirely on what's actually holding your manuscript back. Here's the honest breakdown.
Avoid desk rejection at Lancet Oncology with practice-changing evidence, global relevance, and defensible trial design.
The Cancer Letters cover letter is the first translational-significance argument an Elsevier handling editor reads. Here is what it must say, a copyable template, the declarations Editorial Manager expects, and the opener patterns that survive desk screening.
A package-readiness guide to submitting to Cancers (MDPI): section-scope fit, the SuSy portal, pre-check screening, single-blind review, and the CHF 2,900 APC.
Rejected from Cancer Letters? Six oncology alternatives ranked by fit, plus the Elsevier transfer route and what to fix before resubmitting.
Proposal declined by Nature Reviews Cancer? Six oncology review venues that take unsolicited work, ranked by fit, speed, and APC, plus a reframe plan.
Frontiers in Immunology is not predatory. It has recognized indexing, Q1 ranking, and IUIS backing - but Frontiers' publisher model and Finland's downgrade are worth understanding before you submit.
Frontiers in Microbiology is not predatory. It has recognized indexing, Q1 ranking, and PubMed coverage - but the Frontiers review model and institutional downgrades are worth understanding.
Sustainability is not predatory by standard definitions. It has dual SCIE/SSCI indexing, but Norway removed it from approved lists and Finland downgraded it to Level 0.
Frontiers is not a fake publisher, but its role in pressuring Beall's list offline, its 2025 mass retraction, and Finland's downgrade of 78 journals mean the answer requires journal-level judgment.
Sensors is not predatory. It has SCIE and Scopus indexing, but MDPI's special issue dominance and fast review timelines are the real concerns.
If PLOS ONE sent your manuscript back as a major revision, here is what the soundness criterion means for your revision, your three required documents, how the Academic Editor and original reviewers re-review, and how to write the point-by-point response that survives a second round.
If Cell Reports sent your manuscript back as a major revision, here is what the decision means, your roughly two-to-three-month window, how the Cell Press consulting editor and original reviewers re-review, and how to write the point-by-point response that survives a second round.
If Cell sent your manuscript back as a major revision, here is what the decision means, your 2-to-3-month revision window, the one-major-revision limit, how the original Cell Press reviewers re-review, and how to write the point-by-point response to reviewers that survives a second round.
If International Journal of Molecular Sciences sent your manuscript back as a major revision, here is what the decision means, your fast MDPI resubmission window, how the academic editor and original reviewers re-review, and how to write the point-by-point response that survives a second round.
What a Nature Communications major revision means, how the two-month deadline works, and how to prepare a response that can survive re-review.
If Nature sent your manuscript back as a major revision, here is what the decision means, your two-month deadline, how the original referees re-review, and how to write the response to referees that survives a second round.
If your PNAS manuscript came back as a major revision, here is what the decision means, your two-month resubmission deadline, how the original reviewers re-review, and how to write the point-by-point response that survives a second round.
If your Science manuscript came back as a major revision, here is what the decision means, what your odds are, and how to write the point-by-point response that survives re-review.
If Scientific Reports sent your manuscript back as a major revision, here is what the decision means under its soundness-only model, the deadline, how the Editorial Board Member re-reviews, and how to write the point-by-point response to reviewers that wins.
If you are tracking the 'With Editor' phase at Nature Communications, your paper is in the handling-editor desk screen inside the Under Consideration label, before any referee is invited. Here is what that decision involves and when the wait is normal.
If your Nature submission shows With Editor, the manuscript is in the handling-editor desk screen before any referee is invited. Here is what that decision involves and when the wait is normal.
If your PNAS submission shows With Editor, the manuscript is in editorial screening with an NAS Editorial Board member before any referee is invited. Here is what that decision involves and when the wait is normal.
If your Scientific Reports submission shows With Editor, the manuscript is in the initial quality check and Editorial Board Member screen before any referee is invited. Here is what that decision involves and when the wait is normal.
Before you submit to Science Advances, use this checklist to verify significance, scope fit, data availability, and the items editors evaluate in the first read.
Before submitting to Angewandte Chemie, verify these 10 items covering the novelty argument, characterization completeness, and cover letter strategy that in-house editors evaluate first.
Nature Biotechnology desk rejects ~70% of submissions. Verify these items covering technical innovation, validation depth, scalability, and what editors screen first.
AI screening is no longer hypothetical. Major publishers are using it before peer review, which changes what authors need to catch before they submit.
If an AI review tool cannot explain how it handles confidentiality, citations, evidence, and adversarial inputs, it is not safe enough for a serious manuscript.
What submitting to European Respiratory Journal actually requires: the European Respiratory Society publishing structure, the broad-respiratory-medicine editorial scope, the hybrid open-access model, and the editorial culture distinguishing ERJ from sister respiratory venues (AJRCCM, Lancet Respiratory Medicine, Thorax).
Edanz is best understood in 2026 as a legacy author-service brand whose expert editing has moved into Scribendi Scientific Editing.
Editorial triage risk assessment checks whether a manuscript is likely to fail the editor's first screen before peer review.
This Editverse review explains where its academic editing and publication support may help, and when Manusights is the better first step.
A major revision help service helps authors interpret reviewer comments, prioritize changes, and prepare a response that protects the manuscript.
A manuscript quality check before submission should test whether the paper is ready for editor and reviewer scrutiny, not just whether the files are complete.
This ManuscriptEdit review explains where the service fits, when it may help, and when a manuscript-specific readiness review is the better first step.
PNAS accepts ~16% of direct submissions with a 50-60% desk rejection rate. This guide covers the post-2022 reform landscape, the Significance Statement bar, and how PNAS compares to Nature Communications.
Advanced Energy Materials requires quantified device performance data with energy relevance. Understand the IF 24.4, 15-20% acceptance rate, and how AEnM differs from AFM.
Pre-submission guide for Hepatology covering AASLD editorial standards, word limits, and what separates viable liver research from desk rejects.
PLOS ONE is commonly estimated to accept about ~31% of submissions based on rigor, not novelty. This guide covers the soundness-over-impact model, data sharing requirements, APC, and what editors actually check.
Applied Sciences (MDPI) charges CHF 2,400 (~$2,600) for open access. Gold OA megajournal with 30K+ papers/year. Comparison with PLOS ONE, Sensors, IEEE Access.
Applied Sciences has no strict word limit (4,000-8,000 words typical) and requires the MDPI template for all submissions. The abstract is ~200 words, references use MDPI numbered style with square brackets, and both Word and LaTeX are accepted.
BMJ Open uses open peer review and mandatory reporting checklists. Missing a checklist is the single most common trigger for desk rejection, and it is entirely preventable.
Cancer Research limits Articles to 5,000 words with a 250-word structured abstract and up to 7 figures. References use AACR numbered style with parenthetical citations, and a Significance statement is mandatory for all research articles.
Cell formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
Cell Reports formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
EMBO Journal editors are screening for mechanistic molecular biology with real biological consequence. A strong cover letter makes that balance obvious fast.
Frontiers in Plant Science formatting guide: word limits, figure specs, author-year references, LaTeX vs Word, and journal-specific quirks.
Genome Biology has no strict word limit for Research articles. Structured abstracts use Background/Results/Conclusions headings, BMC numbered references, and strict data/code public availability is mandatory.
ACS Catalysis demands mechanistic depth beyond activity data. Understand the editorial bar, IF 13.1, 20-25% acceptance rate, and how it compares to Journal of Catalysis.
ACS Nano requires genuine nanoscale science where size-dependent properties drive the findings. Learn the scope fit, acceptance rate, and how it differs from Nano Letters.
Advanced Functional Materials prioritizes demonstrated function over pure novelty. Learn the acceptance rate, scope fit, and how AFM differs from Advanced Materials.
Analytical Chemistry requires rigorous method validation and comparison data. Learn the 25-30% acceptance rate, what ACS editors screen for, and how it compares to Analytica Chimica Acta.
Angewandte Chemie International Edition desk-rejects about 50% of submissions. Master the 2,500-word Communication format, VIP designation, and what GDCh editors screen for.
Angewandte Chemie values novelty and concise Communication format. Understand the 20-25% acceptance rate, editorial screen, and how to frame your chemistry for GDCh editors.
Applied Catalysis B requires environmental or energy catalysis with mechanistic insight and benchmarking data. Learn the IF 22.1, 15-20% acceptance rate, and scope boundaries.
Applied Energy demands engineering-grade energy research with real-world validation data. Understand the 15-20% acceptance rate and how it differs from Energy.
Applied Physics Letters publishes concise 4-page applied physics results. Learn the 45-50% acceptance rate, format constraints, and when to choose APL over JAP.
Applied Sciences (MDPI) is commonly estimated to accept about 45-50% of submissions and evaluates technical soundness over novelty. Understand the APC, review speed, and when this broad open-access venue is the right fit.
Bioinformatics (Oxford) requires novel algorithms with reproducible, freely available code. Learn the 25-30% acceptance rate, Application Note format, and how it compares to BMC Bioinformatics.
Blood desk-rejects 65% of submissions before external review. Learn the ASH editorial bar, $75 submission fee, article-type limits, and how Blood differs from Blood Advances.
BMJ Open is commonly estimated to accept about 27% of submissions with fully open peer review and named reviewers. Understand the APC, reporting guidelines, and how it compares to PLOS ONE.
The BMJ is commonly estimated to accept about 7% of submissions with open peer review and patient reviewers. Understand the editorial bar, how BMJ compares to NEJM and The Lancet, and what editors prioritize.
CA has the highest IF of any journal in the world, driven by the annual cancer statistics report. It is a solicited review journal. Unsolicited original research is not accepted.
Carbohydrate Polymers demands polysaccharide novelty with applied relevance. Understand the IF 10.7, 20-25% acceptance rate, scope traps, and how it compares to IJBM.
Ceramics International requires ceramic-first scope with novelty in composition or processing. Understand the IF 5.2, 30-35% acceptance rate, and how it compares to JECS and JACerS.
Pre-submission guide for ES&T covering environmental relevance requirements, data quality expectations, and the ACS editorial bar.
Pre-submission guide for Frontiers in Immunology covering section selection strategy, the collaborative review model, and editorial screening criteria.
Pre-submission guide for Frontiers in Microbiology covering section selection, collaborative review process, and what editors check before peer review.
Pre-submission guide for Fuel (Elsevier) covering scope traps, desk-rejection triggers, and how it compares with Energy & Fuels.
Pre-submission guide for Immunity covering mechanistic depth requirements, STAR Methods formatting, human relevance, and the Cell Press editorial bar.
Pre-submission guide for IJHE covering the hydrogen-first scope requirement, electrochemistry fit, and what editors screen for before review.
Pre-submission guide for IJMS covering acceptance rates, special issue strategy, review timelines, and when IJMS is the right target.
Pre-submission guide for JAMA Oncology covering the 48-hour desk screen, oncology scope requirements, and what editors actually prioritize.
Pre-submission guide for JAMA covering general-medicine fit, structured abstract rules, and how the journal differs from NEJM.
Pre-submission guide for JCI covering translational depth expectations, data-display rules, sex-as-variable analysis, and title constraints.
Pre-submission guide for Journal of Alloys and Compounds covering structure-property requirements, inorganic materials scope, and editorial expectations.
Pre-submission guide for JBC covering mechanistic biochemistry fit, the open-access model, and what ASBMB editors screen for.
Pre-submission guide for Journal of Cleaner Production covering quantified sustainability impact requirements and what editors screen for.
Pre-submission guide for Journal of Hazardous Materials covering hazard-first framing, realistic matrices, and editorial screening criteria.
Pre-submission guide for Journal of Materials Chemistry A covering energy and sustainability materials scope, the RSC A/B/C split, and common rejection triggers.
Pre-submission guide for JPC C covering surface science scope, APC details, comparison with Langmuir and PCCP, and editorial screening criteria.
Materials (MDPI) has an IF of ~3.1 and accepts 40-45% of submissions with a ~$2,600 APC. This guide covers what editors screen for, scope boundaries, and how it compares to competitors.
Molecular Cell is commonly estimated to accept about 15-18% of submissions and desk-rejects 65-70%. This guide explains the mechanism-first editorial standard and what Cell Press editors screen for.
Nature Communications JIF 15.7 and a ~$7,350 APC. This guide covers editorial expectations, the Nature cascade system, and when Nat Comms is the right target.
Nucleic Acids Research has three editorial tracks: standard research, Database Issue, and Web Server Issue. This guide covers fit, deadlines, APC, and what NAR editors expect.
Nutrients (MDPI) has an IF of ~4.8, accepts 40-45% of submissions, and charges a $2,900 APC. This guide covers what editors screen for, MDPI dynamics, and how it compares to BJN and EJN.
Remote Sensing (MDPI) is commonly estimated to accept about 40-45% of submissions with an IF of ~4.2 and a $2,700 APC. This guide covers scope, review speed, and how it compares with RSE and IEEE TGRS.
Science of The Total Environment publishes 15,000+ papers yearly with an IF of ~8.0 and 25-30% acceptance. This guide covers what editors screen for and how to avoid desk rejection.
Sensors (MDPI) publishes 8,000+ papers yearly across all sensing technologies with an IF of 3.5 and 40-45% acceptance. This guide covers scope, special issues, and when Sensors fits your work.
Oncology manuscripts face unique scrutiny on clinical endpoints, translational depth, patient outcomes, and reporting standards. Here is what reviewers at top oncology journals actually look for.
Chemistry manuscripts face specific scrutiny on characterization completeness, novelty assessment, and benchmarking against existing methods. Here is what JACS and Angewandte Chemie reviewers look for.
Cell biology manuscripts need multi-system validation, mechanistic depth beyond observation, and publication-quality imaging. Here is what reviewers at top cell biology journals expect.
Ecology and evolution manuscripts need robust field data, proper sampling design, and conclusions that scale appropriately from the study system to broader principles.
q.e.d is one of the more differentiated AI tools in this space because it focuses on claim structure and evidence logic, but its manuscript-rights language deserves close reading.
A practical IJMS submission process guide covering the MDPI portal workflow, academic editor assignment, review stages, and what to expect at each step.
eLife's editorial screen rejects 80-85% of submissions, but the reviewed preprint model means every paper that passes gets public reviews and an eLife Assessment. Verify readiness before entering a transparent process.
A practical Nature Chemical Biology submission process guide covering the Nature portfolio portal workflow, editorial triage, dual-discipline review, and what to expect.
Biotech and pharma teams lose months not because the data are weak, but because the first submission overstates translational consequence or targets the wrong journal. Here is how to prevent both.
Pre-submission review career-critical papers: protect tenure, fellowship, and job-market timelines from avoidable rejection.
Before submitting to Nature, verify these 12 items covering breadth of significance, data availability, reporting completeness, and what editors evaluate in the first 5 minutes.
A practical Nature Chemical Biology fit verdict with JCR 2024 comparisons to JACS, Angewandte, and ACS Chemical Biology, plus career impact analysis.
You've finished the draft. You're ready to submit. But are you? Here are the warning signs that your paper needs more work.
If your Biomaterials submission shows Under Review, here is what the Elsevier editors are doing during each stage and when to follow up.
If your Developmental Cell manuscript shows Under Review, here is what the Cell Press editor and reviewers are likely doing.
If your Journal of Clinical Oncology manuscript shows Under Review, here is what ASCO and the editor may be doing and what to prepare next.
If your Trends in Molecular Medicine submission shows Under Review, here is how to interpret Cell Press routing and what to prepare next.
If your Science submission shows Under Review, here is what AAAS editors and the Board of Reviewing Editors are doing during each stage and when to follow up.
What submitting to The Lancet actually requires: the Elsevier publishing structure, the broad clinical-medicine + global-health editorial scope, the Lancet-family routing across specialty Lancet journals, and the editorial culture distinguishing The Lancet from sister Lancet titles and competing top medical venues.
A practical Journal of Nanobiotechnology submission guide for authors deciding whether the manuscript is truly nano-bio enough, biomedical enough, and complete enough for editorial screening.
A practical Lancet Oncology submission guide for authors deciding whether the paper is clinically mature, globally relevant, and package-ready.
If your European Respiratory Journal manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your JAMA Network Open manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
If your Nature Reviews Cancer manuscript shows Under Consideration, here is what the editor and reviewers are likely doing and when to follow up.
If your PNAS Nexus manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
A practical Genes & Development submission process guide covering what happens after upload, what editors screen first, and what to fix before submission.
A practical Cancer Cell submission process guide covering portal steps, cover letter framing, and editorial screening. See the full timeline.
A practical Nature Chemical Biology submission guide covering the interdisciplinary framing requirement, cover letter strategy, and what must be true before your paper enters review.
A package-readiness guide to JAMA Oncology covering Key Points, structured abstract discipline, endpoint logic, and what must be stable before submission.
A practical Angewandte Chemie International Edition submission process guide covering the Editorial Manager workflow, editor triage, review stages, and what each decision means.
What submitting to JAMA Network Open actually requires: the AMA publishing structure, Eli N. Perencevich's editorial leadership, the open-access model, the broad clinical-research scope, and the editorial culture distinguishing it from sister JAMA-family specialty journals.
A practical Nature Metabolism submission guide for authors deciding whether metabolism is truly the paper's core story and whether the package already meets a Nature-level editorial screen.
A practical Nature Reviews Cancer submission guide for authors deciding whether a review concept is broad, authoritative, and timely enough to pitch.
A practical Cancer Research submission guide covering package readiness, broad-oncology fit, and what to tighten before upload.
A practical JCI submission guide for authors deciding whether the manuscript truly advances the practice of medicine, or is still better owned by a narrower specialty journal.
A practical PNAS Nexus submission guide for authors deciding whether the paper is broad enough, cross-disciplinary enough, and finished enough for this NAS journal.
Trends in Molecular Medicine is not a default outlet for standard primary research. This guide explains what to pitch, what article types actually work, and how to avoid mis-targeting the journal.
A practical Clinical Cancer Research submission guide focused on package readiness, translational fit, and what should already be true before upload.
What submitting to Sports Medicine actually requires: the Adis/Springer publishing structure, the systematic-review-and-meta-analysis editorial scope, the broad sports-medicine + exercise-science scope, and the editorial culture distinguishing the journal from sister sports-medicine venues.
A practical Nature Cell Biology submission guide focused on mechanistic fit, conceptual breadth, and what the package should already prove before submission.
A package-readiness guide to eLife covering preprint readiness, public-review fit, evidence strength, and what must be stable before submission.
A practical guide to the proposal and article ideas Trends in Molecular Medicine screens out before review, and what a viable pitch needs instead.
A practical memo on why Genes & Development desk-rejects manuscripts and what authors need to make obvious before the first editor finishes the abstract and opening figures.
A practical memo on why Cell Discovery desk-rejects manuscripts and what authors need to make obvious before the first editor finishes the abstract and opening figures.
A practical memo on why Developmental Cell desk-rejects manuscripts and what authors need to make obvious before the first editor finishes the abstract and opening figures.
how to avoid desk rejection at JAMA Oncology. Practical guidance for JAMA Oncology, plus what authors should do next. See how to avoid it.
Avoid desk rejection at Cancer Cell with broader consequence, translational weight, and a fully integrated package.
Avoid desk rejection at Nature Genetics with enough scale, stronger interpretation, and defensible population design.
How to avoid desk rejection at Nature Medicine: disease mechanism, human relevance, and clinical consequence.
How to avoid desk rejection at Nature Reviews Cancer: commissioned-level synthesis, timing, and field authority.
How to avoid desk rejection at Science Advances: what editors screen first on breadth, rigor, and cross-disciplinary significance.
What Annals of Oncology editors screen for before peer review, and the missing pieces that make an oncology paper look promising but still too early.
How to avoid desk rejection at Clinical Cancer Research: translational depth, stronger models, and patient-facing logic.
How to avoid desk rejection at Journal of Clinical Oncology: practice-changing evidence, definitive methods, and clinical consequence.
If your Aging Cell submission shows Under Review, here is what the Supervising Editor and Editor-in-Chief are doing during each stage and when to follow up.
If your Science Advances submission shows Under Review, here is what the AAAS deputy editors and associate editors are doing during each stage and when to follow up.
If your Scientific Reports submission shows Under Review, here is what the Editorial Board Member is doing during each stage and when to follow up.
If your PLOS ONE submission shows Under Review, here is what the in-house handling editor and Academic Editor are doing during each stage and when to follow up.
If your American Journal of Human Genetics submission shows Under Review, here is what the Cell Press associate editor is doing during each stage and when to follow up.
If your Cancer Research submission shows Under Review, here is what the AACR Senior Editor is doing during each stage and when to follow up.
If your International Journal of Molecular Sciences submission shows Under Review, here is what the MDPI handling editor and academic editor are doing during each stage and when to follow up.
JCB advertises a very fast editorial screen, but accepted papers still show a wide spread depending on how much revision the paper needs.
JAMA Oncology often tells authors relatively quickly whether a paper belongs in top-tier clinical oncology, but the real submission question is methodological and clinical consequence, not just speed.
JCO usually tells authors relatively quickly whether a paper belongs in flagship clinical oncology, but the real submission question is practice-changing consequence, not just speed.
Nature Genetics often tells authors relatively quickly whether a paper belongs in flagship genetics, but the real submission question is field-level genetic consequence, not just speed.
A practical Developmental Cell submission guide focused on mechanistic fit, live-imaging expectations, and what the package should already prove before submission.
A practical guide to submitting to Cancer Cell, including how editors think about fit, patient relevance, mechanistic depth, and package readiness.
A practical Current Biology submission guide: how to judge fit, shape the story, prepare the package, and avoid obvious editorial misses.
A package-readiness guide to Cell Reports: choose the right format, shape the story, stabilize STAR Methods, and avoid desk rejection.
If your Nature submission shows Under Review, here is what professional Nature editors are doing during each stage and when to follow up.
If your Cell submission shows Under Review, here is what Cell Press editors are doing during each stage and when to follow up.
If your PNAS submission shows Under Review, here is what the NAS Editorial Board member and member editor are doing during each stage and when to follow up.
If your Cancer Cell submission shows Under Review, here is what Cell Press editors are doing during each stage and when to follow up.
If your Cell Reports submission shows Under Review, here is what Cell Press editors are doing during each stage and when to follow up.
If your Current Biology submission shows Under Review, here is what Cell Press editors are doing during each stage and when to follow up.
If your Gastroenterology submission shows Under Review, here is what AGA editors are doing during each stage and when to follow up.
If your Genome Biology submission shows Under Review, here is what BMC editors are doing during each stage and when to follow up.
If your Molecular Cell submission shows Under Review, here is what each status means, what Cell Press editors are doing during each stage, and when to follow up.
If your Nature Cell Biology submission shows Under Review, here is what Nature Portfolio editors are doing during each stage and when to follow up.
If your Nature Methods submission shows Under Review, here is what Nature Portfolio editors are doing during each stage and when to follow up.
If your PLOS Medicine submission shows Under Review, here is what the in-house editors and Academic Editor are doing during each stage and when to follow up.
A practical Developmental Cell submission process guide covering what happens after upload, what editors screen for first, and what to tighten before you submit.
Avoid desk rejection at JECCR with a stronger translational bridge, more actionable oncology consequence, and a cleaner bench-to-bedside first read.
Avoid desk rejection at Journal of Nanobiotechnology with a stronger nano-bio interface, better validation, and cleaner journal fit.
Avoid desk rejection at Nature Metabolism by making metabolism the real story, not a supporting result inside another field.
A practical memo on why Nature Cell Biology desk-rejects manuscripts and what authors need to make obvious before the first editor finishes the abstract and opening figures.
A practical memo on why Nature Structural & Molecular Biology desk-rejects manuscripts and what authors need to make obvious before the first editor finishes the abstract and opening figures.
A workflow-focused Nature submission process guide covering what happens after upload, what triage is testing, and where papers lose time.
A practical Science of the Total Environment submission process guide covering the Elsevier Editorial Manager workflow, editorial screening, review stages, and what to expect.
A workflow-focused Nature Methods submission process guide covering what happens after upload, what editors screen for first, and where method papers usually lose momentum.
A practical Science Translational Medicine submission process guide covering what happens after upload, what editors judge first, and what to fix before you submit.
A practical guide to what the RSC Advances submission process usually looks like, what editors judge early, and what slows a chemistry paper down.
A practical Nature Structural & Molecular Biology submission guide focused on structure-function fit, mechanistic validation, and what the package should already prove before submission.
ACS Nano submission process guide to evidence-package triage, SI risk, reviewer routing, and what to fix before upload.
A practical Hepatology submission process guide: how the portal works, what editors are deciding early, and what usually weakens a liver-paper submission.
Nature Communications impact factor is 15.7. Five-year JIF is 17.2. Quartile: Q1. Category rank: 10/135.
Nature desk-rejects more than 90% of submissions, usually within 4-6 weeks. For papers that reach peer review, total time to a first decision runs 4-6 months. Here's what the timeline looks like at every stage.
The best Edanz alternative depends on whether you need scientific editing, journal recommendation, or a submission-readiness verdict.
The best Elsevier Language Editing alternative depends on whether you need English editing, scientific review, journal fit, or readiness feedback.
The best LetPub alternative depends on whether you need scientific editing, journal recommendation, formatting, or readiness review.
The best Nature Research Editing Service alternative depends on whether you need editing, formatting, scientific readiness, or journal-fit judgment.
The best Scribendi Scientific Editing alternative depends on whether you need scientific editing, language polish, journal strategy, or a readiness verdict.
The best Springer Nature Author Services alternative depends on whether you need editing, formatting, translation, or scientific readiness review.
The best Taylor & Francis Editing Services alternative depends on whether you need language editing, formatting, expert review, or readiness strategy.
The best Wiley Editing Services alternative depends on whether the manuscript needs English polish, scientific readiness review, formatting, or broad publication support.
The best Wordvice alternative depends on whether you need language editing, AI writing support, journal-fit review, or scientific readiness feedback.
Cactus Communications is best understood through Editage and its author-services ecosystem, not as a substitute for manuscript readiness review.
Charlesworth Author Services is strongest for editing and author-service support, not for deciding whether a manuscript is ready for a target journal.
A confidential manuscript review service should protect unpublished research while giving useful pre-submission feedback on journal fit, reviewer risk, claims, methods, and figures.
A cover letter review service should test whether the submission letter helps the editor understand fit, novelty, disclosure issues, and reviewer suggestions.
Elsevier Language Editing is best for English clarity before submission, not for deciding whether the science is ready for the target journal.
External peer review before submission helps authors identify likely reviewer objections before a journal editor sends the paper out.
A figure quality check before submission should test whether figures are readable, evidence-bearing, integrity-safe, and compliant with journal requirements.
Edanz can be worth evaluating if you want the Scribendi Scientific Editing successor workflow, but it is not the right first purchase for readiness uncertainty.
Elsevier Language Editing is worth it when the manuscript needs English clarity, not when the real risk is scientific readiness.
LetPub can be worth it for scientific editing and journal recommendation, but it should not be the first purchase when readiness is uncertain.
Nature Research Editing Service is worth it for editing and manuscript preparation, not for acceptance reassurance or journal-fit judgment.
Scribendi Scientific Editing can be worth it when the paper needs scientific editing, but it is not the right first purchase for readiness uncertainty.
Springer Nature Author Services can be worth it for premium editing and preparation support, but not as acceptance reassurance.
Taylor & Francis Editing Services can be worth it for preparation tasks, but readiness review should come first when the manuscript may change.
Wiley Editing Services can be worth it for defined editing and preparation tasks, but readiness review should come first when the real risk is journal fit.
Wordvice is worth it when the manuscript needs academic English editing. It is not the best first buy when the real risk is scientific readiness.
A journal rejection risk check tells authors which rejection mode is most likely before they submit: desk rejection, reviewer rejection, or revision failure.
A journal transfer after rejection can save time, but authors should decide whether the offer fits the manuscript, reviews, and next target.
LetPub is strongest for scientific editing and journal recommendation support, especially when authors need publication-preparation help.
A manuscript gap analysis service finds the missing evidence, explanation, or positioning that could weaken submission.
A manuscript readiness score helps authors convert pre-submission risk into a clear submit, revise, or retarget decision.
Non-native English speakers often need science-first manuscript review before language editing so the paper is not polished before the argument is stable.
Manusights and Edanz solve different pre-submission problems: submission-readiness judgment versus scientific editing through the Edanz/Scribendi transition.
Manusights and Wordvice solve different pre-submission problems: reviewer-risk readiness versus academic English editing.
A medical manuscript review service should test whether a clinical or biomedical paper is ready for journal review, not just edit the English.
A methods review before journal submission checks whether the study design, analysis, reporting, and claims can survive reviewer scrutiny.
Nature Research Editing Service is strongest when authors want publisher-branded editing support, not a guarantee of journal readiness.
A novelty check before submission tests whether the paper's contribution is real, visible, and framed at the right journal level.
Peer review before submission is useful when you need reviewer-style criticism before a journal editor or referee sees the manuscript.
PLOS ONE and Communications Biology both publish open-access science, but Communications Biology has a stronger biology-specific editorial bar.
PNAS and PLOS Biology both publish important biology, but PNAS rewards broad academy-level science while PLOS Biology rewards open-access life-science work with wide biological relevance.
Agricultural science papers need pre-submission review that tests field design, environment coverage, statistics, sustainability claims, and journal fit.
Cancer biology papers need pre-submission review that checks mechanism, model validity, cell-line authentication, validation, and claim discipline.
Climate science papers need pre-submission review that tests methods, uncertainty, data, code, attribution, policy language, and journal fit.
Developmental biology papers need pre-submission review that checks mechanism, imaging, genetics, staging, quantification, data, and journal fit.
Stem cell papers need pre-submission review that tests differentiation evidence, controls, cell-line provenance, ethics, reproducibility, and journal fit.
A publication readiness review gives authors a submit, revise, or retarget decision before the manuscript enters journal review.
Rapid manuscript review before submission helps authors identify the highest-risk issue quickly before journal upload.
A response to reviewers review service checks whether the rebuttal letter is clear, complete, and tied to real manuscript changes.
A reviewer risk assessment tells authors what peer reviewers are likely to attack after the paper clears editorial screening.
A revise and resubmit review service helps authors turn reviewer comments into a resubmission plan before uploading the revised manuscript.
Scribendi Scientific Editing is a serious editing option, but it should not be confused with a submission-readiness verdict.
Springer Nature Author Services is strongest for editing and publication-support workflow, especially when authors want a publisher-branded service.
A statistical review before journal submission checks whether the analysis, reporting, and inference are strong enough for reviewers.
A submission readiness review gives authors a submit, revise, or retarget decision before journal upload.
Taylor & Francis Editing Services is strongest for manuscript preparation, editing, formatting, and pre-submission support, not for acceptance reassurance.
Wiley Editing Services is strongest for editing and preparation tasks, not for deciding whether a manuscript is ready for a target journal.
Wordvice is strongest for academic English editing and proofreading, not for a hard scientific readiness call before journal submission.
Lancet Oncology review time: oncology research with practice-changing implications for clinical oncologists.
Before you submit to Cell, verify these 10 items covering mechanistic depth, first figure impact, breadth of significance, and the specific editorial tests that cause 70-80% of submissions to be desk rejected.
83% of high-impact journals now have AI policies. Here is what you must disclose, what is prohibited, and how to stay compliant across different journals.
JACS desk rejects 40-50% of submissions. Verify these 10 items covering novelty, characterization depth, the title word restrictions, and what associate editors screen first.
Before you submit to Nature Communications, use this checklist to verify scope fit, data availability, reporting completeness, and the specific items editors screen in the first read.
Avoid desk rejection at PNAS Nexus by proving real interdisciplinary value, not just using it as a broad-scope fallback.
JECCR impact factor is 12.8 with a 5-year JIF of 12.2. See rank, trend, and what it means before submission.
Journal of Nanobiotechnology impact factor is 12.6 with a 5-year JIF of 12.3. See rank, trend, and what it means before submission.
Nature Cell Biology moves quickly on immediate rejections, but full review and revision can still take months. Here is the realistic timeline.
Nature Metabolism can reject quickly, but article histories show that accepted papers often spend many months in review and revision. The desk and full-review clocks are very different.
Nature Reviews Cancer is not a standard unsolicited research journal. The timing question starts with commissioning, editorial shaping, and only then formal peer review.
Nature Reviews Molecular Cell Biology is not a standard unsolicited journal path. The process begins with commissioning, editorial shaping, and then formal peer review.
PNAS Nexus review time is not opaque, but the key signal is variability. SciRev points to a relatively quick first round, while official article histories show accepted papers often taking about 4 to 8 months to final acceptance.
Molecular Cell lists a USD 10,400 APC for optional open access. Here is what that price means in practice.
Cell Metabolism lists a USD 10,400 APC for optional open access. Subscription publication is free, so fit, funding, and audience matter most.
Cell Reports is fully open access and currently lists a USD 5,790 APC. Here is what that means for budgeting, GPOA discounts, and journal choice.
Food Chemistry charges a $4,680 APC for open access in 2026. Hybrid model, current timing, institutional coverage, and editorial fit guidance.
ACS Applied Materials & Interfaces APC is $4,500 for CC BY or $4,000 for CC BY-NC-ND, with lower ACS hybrid options.
Advanced Functional Materials charges a $5,790 APC for hybrid open access in 2026. Current Wiley pricing, agreement coverage, and fit.
Analytical Chemistry APC is $4,500 for CC BY or $4,000 for CC BY-NC-ND, with cheaper ACS green and delayed-OA routes.
Annals of Oncology APC is EUR 5,556. Hybrid ESMO pricing, 12-month embargo rules, agreement coverage, and oncology fit guidance.
Applied Catalysis B APC is USD 5,980. Hybrid Elsevier model, 13% acceptance, fast review, and route tradeoffs.
Applied Energy APC is $4,210 under Elsevier's current hybrid model. Current fee, agreement coverage, review timing, and energy-journal comparison.
Applied Surface Science APC is USD 4,210. Gold OA is optional, subscription publishing is free, and Elsevier agreements may cover the fee.
Bioinformatics is now fully open access. OUP uses article-type APCs, ISCB discounts, R&P coverage, and no page or color charges.
Bioresource Technology charges a $4,670 APC for open access in 2026. Hybrid model, current timing, agreement coverage, and manuscript-fit guidance.
Cancer Cell APC is currently $10,400. Hybrid Cell Press pricing, agreement uncertainty, metrics context, and when paying makes sense.
Cancer Research APC runs about $4,200 for AACR members or $5,000 for nonmembers, with page charges on subscription papers.
Cell Host & Microbe APC is currently $10,400. Hybrid Cell Press pricing, agreement uncertainty, metrics context, and fit tradeoffs.
Chemical Engineering Journal APC is USD 5,070. Hybrid Elsevier model, 24-month green OA, and route tradeoffs for CEJ authors.
Chemical Reviews APC is $4,500 for CC BY or $4,000 for CC BY-NC-ND, with lower ACS delayed and green routes.
Clinical Infectious Diseases APC is USD 5,001, and page composition charges still apply. OUP hybrid model and route tradeoffs.
Diabetes Care APC runs about $3,000-$4,000, with page charges on subscription papers and strong clinical-diabetes reach either way.
Current eLife publication fee is $3,000 at peer-review entry. Reviewed-preprint model, waivers, metrics, and when the fee is worth paying.
Energy APC is USD 4,050. Gold OA is optional, subscription publishing is free, and Elsevier agreements often cover the fee.
ES&T is hybrid: subscription is free and ACS routes OA pricing through a live estimator. Agreements, discounts, metrics, and when OA is worth it.
Gastroenterology APC is currently $4,180. Hybrid AGA pricing, immediate accepted-manuscript posting, metrics context, and OA tradeoffs.
Genome Biology APC is USD 5,690 for most article types and USD 4,280 for Brief Reports. Fully OA with Springer support.
IEEE Access APC is $2,160. IEEE members get 5% off and IEEE society members get 20% off. Current fully open-access pricing and discounts.
JAMA Oncology is better judged through practice-changing clinical evidence than through a guessed acceptance percentage. The current official signal is clearer than it used to be.
JAMA Oncology's current APC is $6,000 for eligible gold OA articles. Standard publication is free, with delayed access after 12 months.
Journal of Cleaner Production charges a $4,620 APC for open access in 2026. Hybrid model, 24-month embargo, agreements, and fit.
JCO is better judged through practice-changing clinical evidence than through a guessed percentage. The useful question is whether the study clears the ASCO flagship evidence bar.
JCO APC planning is simple: the standard route is free, while the optional OA upgrade does not have one clean fixed public ASCO sticker price.
Journal of Hazardous Materials charges a $4,900 APC for open access in 2026. Hybrid model, subscription route, agreements, timing, and editorial fit.
Journal of Immunology APC is $2,800 for AAI members and $3,500 for nonmembers. Standard publication costs $1,500 or $1,875.
Journal of Materials Chemistry A APC is GBP 3,100. Gold OA is optional, subscription publishing is free, and RSC agreements may cover the fee.
Journal of Power Sources APC is USD 4,150 for OA; subscription is free. Current metrics, agreements, waivers, and whether OA is worth paying.
Nature Biotechnology charges $12,850 for open access. Current pricing, institutional coverage, and waiver support.
Nature Communications APC is $7,350 / EUR 6,150 / GBP 5,490. Current fully open-access pricing, funding support, waiver policy, and journal context.
Nature Immunology charges $12,850 for open access. Current Nature Portfolio pricing, agreement coverage, waivers, and immunology-journal comparisons.
Nature Medicine charges $12,850 for open access. Current pricing, institutional coverage, and waiver support.
Nature Methods charges $12,850 for open access. Current Nature Portfolio pricing, agreement coverage, waivers, and methods-journal comparisons.
NAR is fully open access and currently charges $4,192. Current OUP pricing, agreements, waivers, metrics, and whether the APC is worth paying.
RSC Advances APC is £2,200 for 2026 submissions, with lower-country discounts and waivers. Current metrics and whether the fee is worth it.
Scientific Reports APC is $2,850 / €2,490. Fully open access, funding coverage, metrics context, and when the fee is worth paying.
Water Research APC is $4,840 under Elsevier's current hybrid model. Current fee, agreement coverage, timing, and water-journal comparison.
Cell Stem Cell submission process. Practical guidance for Cell Stem Cell, plus what authors should do next. See the full timeline from upload.
A workflow-focused JAMA Oncology submission process guide covering what happens after upload, what triage is testing, and where papers lose time.
Advanced Materials takes 6-12 weeks to a first decision for papers that pass desk review. Desk rejection decisions arrive in 2-4 weeks. Here's a realistic timeline breakdown for one of materials science's top journals.
A practical NSMB fit verdict for authors deciding whether their structural biology paper is mechanistically strong and broad enough.
Review speed is one of the most misread journal signals. Fast decisions can mean efficient editorial systems, harsh desk triage, or both.
Cancer Cell review time splits into a very fast desk screen and a costly flagship review path. Here's the full timeline, what editors want, and why most papers do not make it past screening.
Paperpal is a $25/month AI writing assistant from Cactus Communications. It handles grammar, paraphrasing, and academic English well. It does not handle scientific review at all.
Materials science manuscripts face specific scrutiny on characterization completeness, performance benchmarking, and data presentation. Here is what reviewers at top materials journals actually look for.
Computational biology manuscripts face unique reproducibility scrutiny. About half of published computational models are not reproducible. Here is what to verify before submission to avoid being part of that statistic.
Environmental science manuscripts need field data, cross-compartment thinking, and realistic application context. Here is what reviewers at STOTEN, Environmental Pollution, and Water Research expect.
Genetics manuscripts face increasing scrutiny on ancestry diversity, functional follow-up of association signals, and statistical genetics methodology. What reviewers at top genetics journals expect.
Engineering manuscripts face specific scrutiny on practical validation, real-world benchmarking, and scalability. Here is what reviewers at top engineering journals expect.
Journals can sometimes spot AI-assisted writing, but the bigger risk is not the detector. It is the manuscript errors, citation problems, and disclosure mistakes that AI leaves behind.
Annals of Oncology moves quickly on low-priority papers, but manuscripts that clear triage still face a selective multi-week oncology review path.
Developmental Cell cover letters work when they explain the developmental process, the causal mechanism, and why the package is shaped correctly for the journal.
Developmental Cell formatting is really mechanism formatting: article type, 150-word summary, STAR Methods, graphical abstract, and dynamic evidence all have to support one developmental claim.
Developmental Cell is not usually slow because the editors are indecisive. It is slow because the journal asks for mechanistic completeness and that stretches the full revision path.
Nature Chemical Biology cover letters work when they show that chemistry unlocks biology, biology justifies the chemistry, and the paper belongs in an integrated journal.
Nature Chemical Biology formatting problems are usually package problems: a review-ready manuscript file, a concise abstract, chemistry-grade characterization, biology-grade controls, and one integrated chemical biology story.
NSMB cover letters work when they explain the mechanistic question, the structure-function payoff, and why the evidence already solves the right problem.
NSMB formatting problems are usually structure-function package problems: a review-ready manuscript, a concise argument, structural validation support, and supporting files that reinforce one mechanistic story.
Trends in Molecular Medicine is a review and opinion journal, so the first timing question is whether the editor wants the thesis at all, not how fast reviewers answer.
Most researchers do not need both services at the same time. They need the right one first. Here's how to tell whether your manuscript needs editing, scientific review, or a diagnostic step before either.
Many buyers do not know how to judge a pre-submission review report before paying for one. This page shows what a useful report should contain, what weak reports look like, and how to tell whether the feedback is actionable.
ACS Catalysis editors are screening for mechanistic insight, not just strong catalytic performance data. A strong cover letter makes that depth obvious fast.
Cell Reports editors are screening for genuine biological insight, not just competent execution. A strong cover letter makes that fit argument obvious fast.
ChemComm editors are screening for novelty and urgency in short-format chemistry. A strong cover letter makes the case for a rapid communication obvious fast.
JCO editors are screening for evidence that could change what oncologists do in clinic. A strong cover letter makes that practice consequence obvious fast.
Nature desk-rejects roughly 93% of submissions. The best pre-submission review for Nature tells you whether your paper passes the real editorial gate before the editors decide for you.
Enago's Lite and Full review tiers solve different problems. This page breaks down what changes when you move from AI-plus-human validation to the broader human-review workflow.
PaperReview.ai is one of the more interesting free AI review tools because it shows its workflow and limits clearly, but it is still a first-pass triage product.
Rigorous is interesting because it is explicit about being an ETH Zurich project exploring AI-supported review, but the terms make clear it is not formal peer review.
A practical Advanced Materials submission process guide covering the Wiley submission portal, editorial screening, review stages, and what to expect at each step.
A practical Cancer Research submission process guide covering what happens after upload, what editors test first, and where oncology papers usually lose momentum.
Blood submission process guide covering editorial triage, reviewer assignment, first-decision timing, and common causes of delay.
A buyer's guide to pre-submission manuscript review services, with a cleaner split between scientific review, editing support, and AI-first tools.
Most PhD students learn what reviewers want by getting rejected first. Pre-submission review compresses that learning curve from months to minutes - starting free.
Pre-submission review grant applications: check timeline risk, journal fit, and manuscript readiness before funding deadlines.
For postdocs, one avoidable rejection cycle can cost a faculty search season, a fellowship deadline, or months of career momentum. Here is how to reduce that risk before you submit.
First high-impact submissions fail for recognizable reasons: wrong journal, weak significance framing, missing experiments, and citation gaps. Here is how to catch these before the editor does.
Enago is stronger as a broad publication-support vendor with a clearer multi-reviewer lane. Manusights is stronger as a lower-cost readiness diagnosis before submission.
Editage is strongest when you want a large publication-support vendor with editing, submission help, and a technical pre-submission review lane.
A practical Lancet Oncology submission process guide covering what happens after upload, what editors screen first, and where papers lose momentum.
Manusights and ManuscriptsReviewer both offer pre-submission peer review, but they differ in reviewer credentials, pricing model, and what the review actually covers. Here's the direct comparison.
AI peer review is genuinely useful. It's also genuinely limited in ways that matter for specific manuscripts. Here's the clear line between when AI feedback is sufficient and when you need a human scientist who's published at your target journal's tier.
Infectious disease publishing spans clinical journals, microbiology journals, and translational hybrid venues. Each has specific reviewer expectations. Here's how to prepare a manuscript that's positioned correctly for the journal you're targeting.
Reviewer3 is a real AI peer review service used by thousands of researchers. Whether it's worth paying for depends on what your manuscript actually needs. Here's the honest breakdown.
Research Square is a preprint server, not a pre-submission review service. If you need manuscript feedback before going public, here are the alternatives that actually review your science.
AuthorONE gives you modular technical reports. If you want a unified readiness answer instead, the best alternative depends on whether formatting or science is the real risk.
Grammarly is useful, but most researchers outgrow it when the problem shifts from grammar to discipline-specific language, citation hygiene, and submission risk.
Paperpal is useful when you want one recurring writing assistant for academic work. It becomes less convincing when your main question is scientific readiness, not wording.
Penelope.ai checks journal formatting requirements. If that is your problem, the alternatives are other compliance tools. If the problem is deeper, you need a different category.
Trinka is the cheapest academic grammar tool at $7/month. The best alternative depends on whether you need better writing help or a completely different category of manuscript support.
Writefull is trained on published papers and has the best Overleaf integration. The best alternative depends on whether you need a different writing tool or a different kind of manuscript help.
Conflicting reviewer comments are not a special failure state. They are a normal part of peer review, and what matters is whether you can show the editor that you saw the conflict and made a defensible tradeoff.
A revision-extension request is not a confession of weakness. It is a communication problem. If you ask early, explain the real constraint, and propose a credible date, editors usually read it differently from a last-minute scramble.
A good reviewer-response document is not polite theater. It is a technical argument map that makes it easy for the editor and reviewers to see that you understood the critique and acted proportionately.
A rebuttal letter is not where you vent, grandstand, or try to outwrite the reviewers. It is where you make the editor's next decision easier.
AuthorONE is worth it if you need automated journal-template formatting and reference management. It's not worth it if you think you're buying a pre-submission review.
Grammarly is useful for cleanup, tone, and sentence-level polish. It is not a serious substitute for manuscript review, journal-fit judgment, or field-specific scientific critique.
Penelope.ai checks whether manuscripts meet journal formatting requirements. It is strong for compliance. It does not evaluate whether the science is good enough.
Research Square is a preprint platform with Springer Nature journal partnerships, not a manuscript review service. It offers visibility and DOIs. It does not tell you if your paper is ready.
Trinka is the cheapest dedicated academic writing tool at $7/month with strong medical and technical English support. It is not a scientific review product.
Writefull is trained on published research papers, not generic prose. That makes it one of the more credible academic writing tools. It is still a writing assistant, not a manuscript review.
Peer review feels opaque because journals show you status labels, not the actual decision logic beneath them. This guide makes the process legible from submission through revision and acceptance.
Peer review in 2026 is not broken in one single way. It is being pulled in several directions at once: toward transparency, toward automation, toward stronger integrity screening, and toward new pressure around reviewer labor. The result is a system that is still recognizable, but no longer static.
Paper rejected from Neuron? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Cell? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Rejected from The Lancet Oncology? 7 top alternative journals including JCO, Annals of Oncology, and Nature Medicine, ranked by scope and study type.
Paper rejected from Nature Biotechnology? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Nature Communications? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison.
Paper rejected from Nature Genetics? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Nature? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Science? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Pre-submission guide for JCO covering the guideline-changing evidence bar, Phase 3 requirements, clinical impact, and ASCO editorial fit.
If your Nature Biotechnology submission shows Under Consideration, here's what's happening, how long each stage takes, and what outcomes to expect.
If your Nature Medicine submission shows Under Consideration, here's what each status label means, how long each stage typically takes, and when it's appropriate to follow up.
If your Nature Methods submission shows Under Consideration, here's what each status means, typical timelines, and what to expect at each stage.
After rejection from Advanced Materials, your best next journals include Advanced Functional Materials, ACS Nano, Advanced Energy Materials, and Chemistry of Materials, depending on your subfield and rejection reason.
After rejection from Blood, the best alternative journals include Leukemia for malignant hematology, Haematologica for European research, Blood Advances as the ASH companion, and JCO for clinical hematology-oncology.
Paper rejected from Cancer Cell? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Cell Metabolism? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Cell Reports? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
After rejection from Chemical Reviews, the strongest alternatives are Chemical Society Reviews for broad chemistry, Coordination Chemistry Reviews for inorganic work, and Accounts of Chemical Research for shorter personal accounts.
After rejection from eLife, consider PLOS Biology for open-access biology, EMBO Journal for molecular and cell biology, Nature Communications for broad scope, or PNAS for cross-disciplinary work.
Rejected from JACS? Here are 7 alternative chemistry journals ranked by scope, selectivity, and publication path, from Angewandte Chemie to Chemical Science.
Rejected from JAMA Oncology? Discover 7 alternative oncology journals, from JCO and Annals of Oncology to JAMA Network Open, ranked by fit for your study type.
Paper rejected from JCI? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Rejected from JCO? 7 alternative clinical oncology journals ranked by fit, including Annals of Oncology, JAMA Oncology, and Clinical Cancer Research.
Paper rejected from The Lancet? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Molecular Cell? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Nature Medicine? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Nature Methods? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Rejected from Nucleic Acids Research? 7 alternative journals for genomics, RNA biology, and bioinformatics papers, from Genome Biology to Bioinformatics.
Paper rejected from PLOS ONE? 7 alternative journals ranked by fit, with acceptance rates and scope. Your best next steps.
Paper rejected from PNAS? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Paper rejected from Science Advances? 7 alternative journals ranked by fit, with IF, acceptance rates, and scope comparison. Your best next steps.
Rejected from Scientific Reports? 7 alternative broad-scope journals including PLOS ONE, PeerJ, and BMC-series titles, with advice on fixing common issues first.
Journal of Hematology and Oncology publishes roughly 1,000 papers per year at IF 40.4. Here is what editors actually screen for, what gets desk-rejected, and how to assess your manuscript's fit.
Lancet Oncology is commonly estimated to accept about 8-10% of submissions. 70-80% desk-rejected. What the numbers mean for clinical oncology authors.
PLOS ONE charges $2,477 for gold open access. Full waivers for low-income countries, institutional All-In deals eliminate fees.
Scientific Reports formatting: Scientific Reports academic editors enforce reproducibility-first review.
eLife editors are screening for papers worth sending into public review, not for prestige theater. A strong cover letter makes the question and evidence quality obvious fast.
The Lancet is for rare hematology papers that become broad clinical events. Blood is for major hematology papers whose real audience is still the hematology field.
The Lancet is for oncology papers that become broad medical events. JAMA Oncology is for high-rigor oncology papers with strong clinical or population-level cancer consequence.
The Lancet is for oncology papers that become broad medical events. The Lancet Oncology is for major oncology papers that belong with oncology readers from the start.
A workflow-focused eLife submission process guide covering what happens after submission, how public review works, and the key stages.
Developmental Cell fit verdict: IF 8.7, Cell Press. Here is when it fits and when Development or Nature Cell Biology is the smarter move.
A practical Nature Cell Biology fit verdict for authors deciding whether their paper is mechanistic, conceptually strong, and broad enough.
A practical Nature Communications fit verdict for authors deciding whether their paper is broad, complete, and credible enough for a selective Nature-branded audience.
Science Advances impact factor is 12.5 in 2024. Here is the trend, the current Q1 context, and how it compares with Nature Communications and PNAS before you submit.
Cell accepts about 8% of submissions. 70-80% desk rejected. Papers reaching reviewers have 25-35% odds. Here's how Cell's editorial process works.
Cell Reports is the Cell Press journal for focused biological insights. Here's when it's the right target and when to aim at Cell, Molecular Cell, eLife, or a specialty journal instead.
A practical Science Advances fit verdict for authors deciding whether their paper is broad, complete, and persuasive enough for a selective cross-field audience.
Scientific Reports and PLOS ONE are both megajournals with technical-soundness-only peer review. The differences come down to field community, publisher brand, and APC structure. Here's how to choose.
Most researchers don't know there are three reliable free ways to look up any journal's impact factor. Here's the fastest method and what to do when IF isn't listed.
If your Nature Communications submission shows Under Consideration, your paper is somewhere between desk review and peer review. Here's what that actually means and when to expect a decision.
Nature accepts breakthroughs. Nature Communications fits strong disciplinary advances. Compare the editorial bar before you submit.
Hepatology editors are screening for real liver-disease consequence and a properly handled study-origin disclosure. A strong cover letter makes both clear fast.
Scientific Reports evaluates technical merit, not perceived impact. A cover letter that argues for novelty is written for the wrong journal. Argue for rigor instead.
Annals of Oncology editors are screening for practice-relevant oncology evidence, not just interesting cancer data. A strong cover letter makes the treatment consequence obvious fast.
Bioinformatics wants the method you built, not the biological finding it produced. If the cover letter leads with biology, the editor will route the paper elsewhere.
Blood editors are screening for real hematology consequence, not just technically solid blood research. A strong cover letter makes that field-level case obvious fast.
Cancer Cell editors are screening for the bridge between mechanism and oncology consequence. A strong cover letter makes that bridge obvious fast.
Cancer Research editors are screening for mechanistic insight into cancer biology, not just strong tumor data. A strong cover letter makes that depth obvious fast.
Cell editors are screening for conceptual advance, not just strong data. A strong cover letter makes that flagship case obvious fast.
Chemical Reviews is primarily invitation-only. If you have not been invited, the path in is a proposal letter, not a traditional cover letter. Here is what editors need to see.
Chemical Society Reviews is primarily invitation-based. If you have not been invited, the path in is a proposal that identifies a coverage gap and makes the case for your team.
Circulation editors are screening for cardiovascular findings that matter beyond a narrow subspecialty lane. A strong cover letter makes that flagship case obvious fast.
Clinical Cancer Research editors are screening for a real bench-to-bedside or bedside-to-bench bridge. A strong cover letter makes that translational logic obvious fast.
At Frontiers in Immunology, the cover letter's main job is routing. Name the specialty section, state the finding, and suggest reviewers who will engage constructively with the collaborative review model.
Frontiers in Microbiology has 25+ specialty sections. The cover letter's main job is getting the paper to the right section editor with enough context for a fast triage decision.
Gastroenterology editors are screening for practice-changing GI findings, not just solid clinical data. A strong cover letter makes the AGA-flagship case obvious fast.
Genome Biology does not want your data. It wants what your data means for biology. A cover letter that reads like a methods summary will be desk-rejected before it reaches a reviewer.
JCI editors are screening for a real translational arc - mechanism connected to human disease. A strong cover letter makes that bench-to-bedside case obvious fast.
JBC is fully open access with no publication fees. The editors are working biochemists who screen for mechanistic depth and molecular-level detail, not impact narratives.
Nature Reviews Cancer does not accept unsolicited manuscripts. Most content is commissioned by in-house editors. If you want to publish here, you need a proposal, not a traditional cover letter.
Nutrients editors screen for nutritional relevance and section fit before anything else. A cover letter that states the dietary or nutritional finding clearly moves through triage fastest.
Trends in Molecular Medicine publishes mostly invited content. You submit a one-page proposal, not a finished manuscript. The editors want a forward-looking argument, not a literature catalog.
Science Advances desk-rejects about 75% of submissions. Your cover letter is the first thing editors read. Here is how to write one that actually works.
Nature Reviews Molecular Cell Biology impact factor is 90.2 with a 5-year JIF of 128.7. Q1, rank 1/204. An invited review journal.
Genome Biology IF 9.4, 5-year JIF 16.3, CiteScore 20, APC $5,490. Year-by-year trend, peer comparisons, and the submission bar explained.
PNAS Nexus received its first JCR impact factor of 3.8 in 2024. Here's what that means, how it compares to PNAS, and whether you should submit there.
Science Advances charges $5K APC and accepts ~10%. PNAS has a free track and accepts ~15%. Which one fits and why it is not just about cost.
JCO has a JIF of 41.9 and CiteScore of 38.9. Here's what those numbers mean for selectivity and realistic submission expectations.
Annals of Oncology impact factor is 65.4. Five-year JIF 46.8, Q1, rank 4/326. See trend, comparisons, and submission guidance.
Cancer Research impact factor is 16.6. Five-year JIF is 13.4. Q1, rank 16/326. See the trend and what it means for authors.
Nature Reviews Cancer impact factor is 66.8 with a 5-year JIF of 81.0. Q1, rank 3/326. An invited review journal with elite citation performance.
Developmental Cell impact factor is 8.7 (JCR 2024). Q1, rank 2/39 in Developmental Biology. Five-year JIF 11.4. APC $9,080.
Science has a JIF of 45.8 and CiteScore of 48.4. Here's how to interpret those numbers and decide if your paper should target Science.
Cell Reports IF 6.9 (JCR 2024), CiteScore 12.9, ~14% acceptance, $5,790 APC. Year-by-year trend, what editors look for, and how it compares to Cell.
American Journal of Human Genetics impact factor is 8.1. Five-year JIF 9.6, Q1, rank 12/191. See comparisons and guidance.
Cell Metabolism impact factor is 30.9. Five-year JIF 30.9, Q1, rank 3/191. See comparisons and what it means for authors.
Genome Research impact factor is 5.5 (JCR 2024). Q1, rank 20/191. Five-year JIF 7.3. h-index 409. See trend, comparisons, and what editors want.
JCB impact factor is 6.4 with a 5-year JIF of 7.2. See rank, quartile, comparisons, and what it means for cell biology authors.
Molecular Cell impact factor is 16.6 with a 5-year JIF of 17.7. See rank, quartile, and what it means for molecular biology.
Nature Cell Biology impact factor is 19.1 with a 5-year JIF of 22.6. See rank, quartile, and what it means for authors.
Nature Metabolism impact factor is 20.8 with a 5-year JIF of 23.2. Q1, rank 5/191. Comparisons, trend, and submission guidance.
Cell impact factor is 42.5 (JCR 2024). CiteScore 74.8, SJR 22.612, Q1. Rank 3/319 in Biology. What the metrics mean for authors.
Citation errors get papers retracted and careers damaged. Here is what live citation verification actually catches, why most review services skip it, and how to check your manuscript before submission.
Most pre-submission review services ignore figures entirely. Here is what figure-level feedback actually catches, why reviewers form their first impression from your figures, and how to get this feedback before submission.
Before you submit to PNAS, use this checklist to verify significance, data requirements, and the specific items editors evaluate after the 2022 editorial reforms.
Thesify is an AI tool for thesis and dissertation feedback with rubric-based evaluation and semantic search. It is best for graduate students, not for journal submission readiness.
A practical Journal of Clinical Investigation submission process guide covering what happens after upload, what editors screen first, and what to fix before you submit.
A practical Nature Biotechnology submission process guide covering what happens after upload, what editors screen for first, and what to fix before you submit.
Nature Genetics impact factor is 29.0 (JCR 2024). Q1, rank 2/191 in Genetics. Five-year JIF 37.4. Acceptance rate, review time, and what editors want.
IJMS is not predatory. It has recognized indexing, Q1 status, and MEDLINE coverage - but its high annual output means quality consistency is the real question.
PLOS ONE requires AI disclosure in Methods and during submission, prohibits AI authorship, and enforces compliance across 15,000+ articles per year through author attestation and community scrutiny.
A ranked guide to the top 14 mechanical engineering journals by scope fit, selectivity, APC, and review time, covering manufacturing, dynamics, solid mechanics, and thermal engineering.
A ranked guide to 14 nanotechnology journals by scope, selectivity, APC, review time, and manuscript fit, covering synthesis, devices, biomedicine, and 2D materials.
Nutrients is not predatory. It has MEDLINE indexing, but the 2018 mass resignation of editors over alleged pressure to accept weaker papers makes it MDPI's most complicated case.
Science requires AI disclosure in three locations (cover letter, acknowledgments, methods), classifies violations as scientific misconduct, and prohibits AI-generated images without editor permission.
Advanced Materials charges ~$5,500-$6,000 for open access. Hybrid Wiley journal, DEAL agreements, IF ~27. Full cost breakdown and how it compares to ACS Nano.
Ranked list of the top 12 condensed matter physics journals by scope fit, selectivity, APC, and review speed, from Nature Physics and PRL to PRB and accessible IOP options.
Ranked list of the top 11 hepatology journals by scope fit, selectivity, APC, and review speed, covering viral hepatitis, MASLD, HCC, liver transplantation, and cholestatic disease research.
A ranked guide to 15 materials science journals by scope, selectivity, APC, review speed, and manuscript fit, with practical advice on choosing the right venue.
A ranked guide to the top 11 structural biology journals by scope fit, selectivity, APC, and review time, covering cryo-EM, crystallography, and NMR venues.
Cell Reports follows the Cell Press AI policy: disclosure goes in STAR Methods, AI cannot be an author, and the same rules apply across Cell Reports Medicine and all Cell Press titles.
The EMBO Journal charges ~$5,450 for open access. Fully gold OA since 2023, Springer Nature partnership, IF ~9. Waivers, deals, and peer comparison.
Hepatology requires AI disclosure in Methods under dual AASLD and Wolters Kluwer rules, prohibits AI authorship and AI-generated images, and applies heightened scrutiny to AASLD practice guideline papers.
Pre-submission guide for IEEE Access covering scope boundaries, the open-access APC model, review speed, and when the journal is the right fit.
PNAS charges $4,975 for immediate OA with site license, $5,475 without. Delayed OA costs $2,575. Full pricing tiers, institutional deals, and funder compliance.
Science Advances follows the AAAS AI policy requiring disclosure in Acknowledgments and Methods, with editors particularly vigilant due to the organization's earlier AI text ban.
Scientific Reports follows Springer Nature's AI policy with Methods disclosure required, enforcing the same rules as Nature across 20,000+ articles per year with reliance on author self-reporting.
ACS Catalysis charges ~$5,000 for open access. ACS hybrid model, Read & Publish deals, member discounts, and comparison with top catalysis journal alternatives.
Angewandte Chemie charges $5,500-$6,000 for open access (hybrid). Free subscription route available. Wiley DEAL agreements, waivers, and cost comparisons.
Annals of Oncology does not publish a strong official acceptance rate. The better submission question is whether the paper is broad and mature enough to matter at ESMO-flagship level.
Applied Physics Letters charges ~$2,500-$3,500 for open access via AIP Publishing. Hybrid model with free subscription-track. Full comparison inside.
Astronomy & Astrophysics charges ~$500-$800 in page charges. Most authors pay nothing due to ESO agreements. How A&A compares to ApJ and MNRAS.
Astrophysical Journal charges $2,300-$3,500+ based on article length. Gold OA since 2022. AAS page charge model explained. How it compares to MNRAS and A&A.
Ranked list of the top 14 agricultural science journals by scope fit, selectivity, APC, and review speed, with guidance on choosing the right venue for your crop science, agroecology, or food systems manuscript.
Ranked list of the top 13 analytical chemistry journals by scope fit, selectivity, APC, and review speed, with guidance on matching your methods paper, sensor study, or separation science work to the right outlet.
Ranked list of 12 astrophysics and astronomy journals by audience, selectivity, costs, and review speed, with advice on choosing between ApJ, MNRAS, A&A, and the Nature portfolio.
Ranked list of the top 12 biochemistry journals by scope fit, selectivity, APC, and review speed, with guidance on placing protein, enzyme, nucleic acid, and chemical biology manuscripts.
Ranked list of the top 12 cardiology journals by scope fit, selectivity, APC, and review speed, covering EHJ, JACC, Circulation and specialty venues for imaging, electrophysiology, and heart failure research.
Ranked list of the top 13 cell biology journals by scope fit, selectivity, APC, and review speed, from Cell and Nature Cell Biology to accessible society journals and OA options.
Ranked list of the top 14 chemical engineering journals by scope, selectivity, APC, and review speed, with guidance on placing reaction engineering, separation, and sustainable process research.
Ranked list of the top 14 civil engineering journals by scope fit, selectivity, APC, and review speed, covering structural, geotechnical, construction materials, and digital construction venues.
Ranked list of the top 14 computer science journals by publishing fit, selectivity, APC, and review speed, with guidance on when to target a journal versus a top conference in ML, systems, and theory.
Ranked list of the top 12 dermatology journals by scope fit, selectivity, APC, and review speed, covering clinical, investigative, surgical, and open-access dermatology outlets.
Ranked list of the top 13 ecology and evolution journals by scope, selectivity, APC, and review speed, with guidance on placing field studies, phylogenetics, and global-change research.
Ranked list of the top 14 electrical engineering journals by scope fit, selectivity, APC, and review speed, spanning power electronics, circuits, communications, and smart-grid research.
Ranked list of the top 12 endocrinology and diabetes journals by scope fit, selectivity, APC, and review speed, with guidance on placing diabetes trials, thyroid research, and obesity studies.
A field-by-field guide to environmental science journal fit, covering water, air, soil, contaminants, sustainability research, accessibility, timing, and publication costs.
Ranked list of the top 14 food science journals by scope fit, selectivity, APC, and review speed, covering food chemistry, hydrocolloids, safety, engineering, and microbiology outlets.
Ranked list of the top 12 gastroenterology journals by scope fit, selectivity, APC, and review speed, covering Gut, Gastroenterology, hepatology companions, and endoscopy outlets.
Ranked list of the top 14 global health journals by scope fit, selectivity, APC, and review speed, with guidance on placing clinical trials, health-systems research, and policy analyses for LMIC settings.
Ranked list of the top 12 hematology journals by scope fit, selectivity, APC, and review speed, covering malignant and non-malignant hematology, hemostasis, and transfusion medicine.
Ranked list of the top 12 immunology journals by scope fit, selectivity, APC, and review speed, covering innate and adaptive immunity, clinical allergy, mucosal immunology, and translational venues.
Ranked list of the top 12 infectious disease journals by scope fit, selectivity, APC, and review speed, covering clinical trials, antimicrobial resistance, surveillance, and emerging-pathogen research.
Ranked list of the top 13 inorganic chemistry journals by scope fit, selectivity, APC, and review speed, with guidance on placing coordination, organometallic, bioinorganic, and catalysis manuscripts.
A ranked guide to the top 14 machine learning and AI journals by venue strength, selectivity, APC, and review time - plus why conferences often matter more than journals in ML.
A ranked guide to the top 13 medical education journals by scope fit, selectivity, APC, and review time - from Academic Medicine and Medical Education to accessible open-access options.
A decision guide to microbiology journals by audience, scope, access model, review path, and whether your manuscript fits ASM, ecology, clinical, or broad microbiology venues.
A ranked guide to the top 12 molecular biology journals by scope fit, selectivity, APC, and review time, from Molecular Cell and NAR to accessible society journals.
A ranked guide to the top 12 nephrology journals by scope fit, selectivity, APC, and review time, from JASN and Kidney International to accessible open-access options.
A ranked guide to the top 14 nursing research journals by scope fit, selectivity, APC, and review time, from IJNS and JAN to accessible open-access options.
A decision guide to oncology journals by study type, clinical audience, selectivity, APC, review time, and publication fit.
A ranked guide to the top 12 ophthalmology journals by scope fit, selectivity, APC, and review time, covering clinical, surgical, and basic science venues.
A ranked guide to the top 13 organic chemistry journals by scope fit, selectivity, APC, and review time, from JACS and Organic Letters to accessible society journals.
A ranked guide to the top 12 particle physics journals by scope fit, selectivity, APC, and review time - including free SCOAP3-funded options for HEP researchers.
A ranked guide to the top 14 pharmacology journals by scope fit, selectivity, APC, and review time, spanning drug discovery, clinical pharmacology, and basic receptor biology.
A ranked guide to the top 13 physical chemistry journals by scope fit, selectivity, APC, and review time, covering spectroscopy, thermodynamics, kinetics, and computational chemistry.
A ranked guide to the top 12 plant science journals by scope, selectivity, APC, and review time, from Nature Plants and Plant Cell to accessible open-access options.
A ranked guide to the top 13 psychiatry journals by clinical fit, accessibility, acceptance rate, APC, and review time.
A ranked guide to the top 13 public health and epidemiology journals by scope fit, selectivity, APC, and review time - from policy-focused Lancet Public Health to accessible OA options.
A ranked guide to the top 12 pulmonology journals by scope fit, selectivity, APC, and review time, from AJRCCM and ERJ to accessible open-access options.
A ranked guide to the top 12 rheumatology journals by scope fit, selectivity, APC, and review time, from Annals of the Rheumatic Diseases and Arthritis & Rheumatology to accessible options.
A ranked guide to the top 15 surgery journals by scope fit, selectivity, APC, and review time, from Annals of Surgery and JAMA Surgery to subspecialty and open-access options.
A ranked guide to the top 13 toxicology journals by scope fit, selectivity, APC, and review time, covering environmental, clinical, regulatory, and mechanistic toxicology.
A ranked guide to the top 12 virology journals by scope, selectivity, APC, and review time - from Nature Microbiology to accessible OA options for fundamental and clinical virology.
Cancer Cell follows the Cell Press AI policy: disclosure goes in STAR Methods, AI cannot be an author, and AI-generated images are banned across all Cell Press journals.
Cancer Cell formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
Carbohydrate Polymers charges ~$4,200 for open access. Elsevier hybrid model, Read & Publish deals, waivers, and comparison with polysaccharide journal.
Cell Press limits AI to readability improvements only, requires disclosure in a dedicated section before References using a provided template, and bans AI-generated images across all Cell Press journals.
Cell charges $11,400 for open access. Hybrid model, excluded from most Elsevier Read & Publish deals. Full cost breakdown, waivers, and alternatives.
Cell Metabolism follows the Cell Press AI policy: disclosure goes in STAR Methods, AI cannot be an author, and AI-generated images are prohibited across all Cell Press titles.
Ceramics International (Elsevier) charges ~$3,800-$4,200 for open access. Hybrid journal, IF ~5, core Elsevier R&P.
Chemical Communications (ChemComm) charges ~$2,000-$2,500 for open access. Hybrid model, RSC Gold for Gold deals, and comparison to Angewandte and JACS.
Chemical Society Reviews charges ~$2,500-$3,000 for open access. RSC hybrid model, invitation-only publishing, and how it compares to Chemical Reviews (ACS).
Circulation requires dual AI disclosure in both Methods and cover letter under AHA rules, prohibits AI authorship and AI-generated images, and bans clinical data processing through external AI tools.
Clinical Cancer Research (AACR) charges $4,200-$5,000 for open access. Hybrid model, AACR member discounts, page charges, and peer journal comparison.
eLife requires AI disclosure in Methods and amplifies accountability through its public peer review model, where reviewer concerns about AI use become permanently visible alongside the published paper.
European Heart Journal requires AI disclosure in Methods under combined ESC and Oxford University Press rules, prohibits AI authorship and AI-generated images, and applies the policy across all ESC journals.
Frontiers in Immunology follows the Frontiers publisher-wide AI policy requiring disclosure, prohibiting AI authorship, and banning AI-generated images across all 200+ Frontiers journals.
Gut follows BMJ Publishing Group's AI policy requiring disclosure in Methods, prohibiting AI authorship and AI-generated images, and applying the same rules as The BMJ across all BMJ specialty journals.
Gut charges ~£2,700 ($3,500) for open access. Hybrid model with strong Jisc coverage. Full cost breakdown, waivers, and comparison to Gastroenterology.
Immunity follows the Cell Press AI policy: disclosure goes in STAR Methods under Method Details, AI cannot be an author, and AI-generated images are banned across all Cell Press journals.
Immunity charges $9,350 for open access. Cell Press hybrid excluded from most Elsevier R&P deals. Full cost breakdown, waivers, and peer journal comparison.
Hindawi was not predatory by standard definitions during its independent years, but after Wiley's acquisition, systematic fraud led to 11,300+ retractions and the brand's complete shutdown by 2024.
Materials (MDPI) is not predatory. It has SCIE indexing, but its high acceptance rate and extraordinary special issue volume are the real concerns.
Molecules is not predatory. It has Scopus Q1 ranking and PubMed indexing, but MDPI's special issue model and 38-day publication speed are the real concerns.
The Astrophysical Journal is commonly estimated to accept about 60-70% of submissions and charges page fees. Learn the AASTeX requirements, arXiv norms, and how ApJ compares to ApJ Letters and ApJ Supplement.
Cancer Cell requires systems-level cancer biology with clinical relevance and STAR Methods. Learn the 8-10% acceptance rate, desk rejection triggers, and pre-submission inquiry process.
Cell Metabolism requires mechanistically complete metabolism stories with in vivo relevance. Understand the 10-12% acceptance rate, STAR Methods requirement, and scope boundaries.
Cell requires mechanistically complete stories validated across multiple systems. Understand the 8% acceptance rate, 85% desk rejection, STAR Methods, and pre-submission inquiry process.
Chemical Engineering Journal requires mechanistic insight alongside engineering applications. Understand the IF 13.3, 22-30% acceptance rate, scope boundaries, and what editors screen for.
Circulation desk-rejects 70% of submissions and requires clinical consequence data. Understand the AHA editorial bar, clinical implications boxes, and how it compares to European Heart Journal.
Construction and Building Materials requires practical construction testing with standards compliance. Learn the 25-30% acceptance rate, durability evidence expectations, and scope boundaries.
eLife charges $3,000 at review commitment and publishes reviewer reports publicly. Understand the assessed preprint model, 15% acceptance rate, and when eLife is the right strategic choice.
Pre-submission guide for IJBM covering editorial screening criteria for proteins, polysaccharides, and biopolymer research.
Readiness checklist for JAMA covering article type fit, statistical review, manuscript components, and when to retarget to a JAMA Network journal.
Pre-submission guide for Journal of Chemical Physics covering chemical-physics fit, theory-experiment rigor, and scope decisions.
Pre-submission guide for Lancet Oncology covering global-trial relevance, policy impact requirements, and the bar for practice-changing evidence.
Pre-submission guide for The Lancet covering global clinical significance, structured abstract requirements, and the bar for practice-changing evidence.
Nature Biotechnology is commonly estimated to accept about 7-10% of submissions and desk-rejects ~70%. The journal publishes new tools and technologies, not biological discoveries made with existing tools.
Nature is commonly estimated to accept about ~8% of submissions and desk-rejects 75-80%. This guide covers what editors screen for in the first 48 hours, common rejection triggers, and the pre-submission enquiry system.
NEJM is commonly estimated to accept about ~5% of submissions and desk-rejects ~90%. This guide covers the clinical practice test, statistical review requirements, and what editors screen for during triage.
NEJM is commonly estimated to accept about 5-7% of submissions and desk-rejects over 90%. This practical guide covers submission requirements, statistical review, cover letter strategy, and article type selection.
RSC Advances is not predatory. It is published by the Royal Society of Chemistry, a learned society with a Royal Charter dating to 1841. The real question is whether it is the right strategic fit for your paper.
JAMA charges ~$5,500 for open access. JAMA Network Open is $3,000 gold OA. AMA institutional deals, waivers, and full cost breakdown.
The JCI requires AI disclosure in Methods, prohibits AI authorship, and sets its own editorial policy through the ASCI rather than inheriting rules from a commercial publisher.
JCI charges $5,300-$5,700 for gold open access. Subscription track is free. Full breakdown of ASCI publishing costs, waivers, and funder compliance.
J Agricultural and Food Chemistry (ACS) charges ~$5,450-$5,500 for open access. Hybrid, IF ~5, ACS R&P deals. Comparison with Food Chemistry, LWT, J Food Sci.
Journal of Alloys and Compounds charges ~$3,800-$4,200 for gold open access. Elsevier hybrid model, R&P deals, waivers. Compared to Materials Letters and more.
JCO requires AI disclosure in Methods under ASCO rules, prohibits AI authorship and AI-generated images, and expects clinical trial interpretations and treatment recommendations to be entirely human-generated.
The Lancet restricts AI to readability and language improvements only, requires disclosure in acknowledgments, and prohibits AI-generated images across all Lancet family journals.
The Lancet charges ~$6,500 for open access. Hybrid model, excluded from most Elsevier deals. Full breakdown of costs, waivers, and Lancet family APCs.
Lancet Oncology restricts AI to readability and language improvements only, stricter than JCO and JAMA Oncology, with disclosure required in the acknowledgments section.
Lancet Oncology charges ~$5,450-$6,500 for open access. IF ~42. Excluded from most Elsevier R&P deals. Full cost breakdown and oncology journal comparisons.
Molecular Cell follows Cell Press AI rules requiring disclosure in STAR Methods, prohibiting AI authorship and AI-generated images, with specific guidance for AlphaFold and cryo-EM workflows.
Nature Biotechnology follows Springer Nature's AI policy with Methods disclosure required, and provides guidance on separating research AI from writing AI in biotech manuscripts.
Nature Genetics follows Springer Nature's AI policy with Methods disclosure required, plus special considerations for genetic data privacy, GWAS pipelines, and variant interpretation.
Nature Genetics charges $12,850 for open access. Springer Nature hybrid model with Read & Publish deals. Comparison with AJHG, Genome Biology, and more.
Nature Genetics is scale-dependent in a way most journals aren't. A 500-person GWAS that would be competitive at a specialty genetics journal won't survive desk review here. Your cover letter has to communicate sample size, effect size, and replication before the editor even opens the manuscript.
Nature Immunology follows Springer Nature's AI policy with Methods disclosure required, plus guidance on single-cell analysis pipelines, immune repertoire data, and clinical immunology considerations.
Nature Methods follows Springer Nature's AI policy with Methods disclosure required, with unique considerations for papers describing AI methods, benchmarking studies, and code availability.
Nature Methods editors are screening for a method other labs will actually use, not just a biological result enabled by one clever tool. A strong cover letter makes that obvious fast.
Nature Reviews Cancer publishes primarily invited Reviews of 8,000-12,000 words. All figures are professionally redrawn by the in-house art team. Nature numbered reference style with 150-300 citations typical.
Nature Reviews Molecular Cell Biology charges $12,850 for open access. Invitation-only model, Springer Nature deals, IF ~80+, and how it compares to NRRC.
NEJM requires AI disclosure in both the cover letter and manuscript, follows ICMJE guidelines prohibiting AI authorship, and its sister journal NEJM AI actively encourages LLM use.
Neuron follows Cell Press AI rules requiring disclosure in STAR Methods, with guidance on separating computational neuroscience research tools from manuscript preparation AI use.
Nutrients is one of the highest-volume nutrition journals, with Q1 ranking and a fast review cycle. Here is what the acceptance data actually tells you.
Nutrients (MDPI) charges CHF 2,900 (~$3,150) for open access. Gold OA, IF ~5. How it compares to Journal of Nutrition, AJCN, and alternatives.
Nutrients formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
PNAS requires AI disclosure in both Methods and Author Contributions, prohibits AI authorship, and applies the same rules across all submission tracks including the NAS contributed track.
Remote Sensing (MDPI) has no strict word limit for research articles but enforces a 200-word abstract cap. MDPI numbered references with full journal names and mandatory MDPI template usage.
Science Advances charges $5,450 for gold open access. AAAS member discounts, institutional deals, and full waivers for developing nations. Complete cost guide.
Science magazine has no standard APC. It's subscription-only for the flagship. Science Advances charges $5,450 OA. Full breakdown of AAAS publishing costs.
Science has 20+ PhD-level in-house editors who desk-reject 75% of submissions. Your cover letter isn't a formality. It's the document that determines whether anyone reads page two of your manuscript.
Sensors (MDPI) has no strict word limit but enforces a 200-word abstract cap. MDPI numbered references with full journal names (not abbreviations), mandatory MDPI template, and performance comparison tables are expected.
Sustainability (MDPI) charges CHF 2,600 (~$2,800) for gold open access. MDPI discount schemes, vouchers, and how it compares to J. Cleaner Production.
Trends in Molecular Medicine charges $6,000-$7,000 for open access. Cell Press hybrid, invited reviews, IF ~12. Deals, waivers, and peer comparison.
Trends in Molecular Medicine formatting guide. Word limits, figure specs, reference format, LaTeX vs Word, and journal-specific formatting quirks you need to know.
Lancet Oncology impact factor is 35.9 (JCR 2024). Q1, rank 8/326 in Oncology. h-index 511. APC $6,300. Trend, acceptance rate, and what editors want.
Current Biology impact factor is 7.5 (JCR 2024). Q1, rank 5/107 in Biology. APC $6,830. See the trend, comparisons, and what editors want.
JAMA is for oncology papers with broad clinical or policy consequence across medicine. Annals of Oncology is for elite oncology papers that are strongest inside the cancer field.
JAMA is for oncology papers with broad clinical or public-health consequence. Journal of Clinical Oncology is for practice-changing papers aimed squarely at oncologists.
JAMA is for oncology papers with broad clinical or policy consequence across medicine. The Lancet Oncology is for flagship oncology papers with international practice consequence.
The Lancet is for oncology papers that become broad medical or global-health events. Annals of Oncology is for top-tier oncology papers that mainly need the oncology field.
The Lancet is for rare oncology papers that become broad medical events. Clinical Cancer Research is for translational oncology papers whose force still depends on oncology readers.
The Lancet is for oncology papers that become broad medical events. JCO is for oncology papers that change practice for oncologists and cancer-care teams.
If the paper is a cancer study with medicine-wide consequence, NEJM is in play. If it's an elite oncology paper that still lives inside oncology, Annals of Oncology is often the sharper target.
NEJM is for rare hematology papers that become broad clinical events. Blood is the flagship first target for many high-impact hematology papers that still belong primarily to the field.
NEJM is for the rare oncology paper that becomes broad clinical medicine. Clinical Cancer Research is for translational oncology work where the bridge from mechanism to patient consequence is the real story.
NEJM is the play for rare oncology papers that become broad medical events. JAMA Oncology is the better first target for high-rigor oncology work with strong clinical or population-level cancer relevance.
For oncology authors, this is often a breadth question. NEJM is for the rare oncology paper that changes medicine broadly. JCO is for oncology papers that change how oncologists treat patients.
NEJM is for oncology studies that become broad medical events. Lancet Oncology is for high-consequence oncology papers with global clinical relevance, especially when the story is still best told inside oncology.
A practical Nature Cell Biology submission process guide covering what happens after upload, what editors screen for first, and what to tighten before you submit.
A practical Nature Structural & Molecular Biology submission process guide covering what happens after upload, what editors screen first, and what to tighten before you submit.
A practical guide to the Astrophysical Journal submission process, including editorial screening, reviewer routing, common delays, and what to tighten.
A practical Clinical Cancer Research submission process guide focused on what happens after upload, what editors test first, and how to interpret early movement.
Non-native English speakers often spend $200-$400 on language editing before learning the paper has scientific problems. The better sequence: free readiness scan first, science review second, language editing last.
Communications Biology vs Scientific Reports compared by editorial standard: significance-led biology vs soundness-only broad science.
A practical Immunity submission process guide covering what happens after upload, what editors screen for first, and what to fix before you submit.
Top oncology journals have among the highest desk rejection rates in medicine. Cancer Cell, JCO, and Cancer Discovery are looking for specific things that most manuscripts don't deliver. Here's what they want and how to close the gap before you submit.
Science of The Total Environment takes roughly 6-10 weeks to a first decision for papers that reach peer review. Desk rejections arrive faster, around 2-4 weeks. Here's what determines your timeline.
International Journal of Molecular Sciences (IJMS) is an MDPI journal known for fast review. First decisions typically arrive in 3-5 weeks. Here's what the timeline looks like and what influences your wait.
Genes & Development is the CSHL Press journal for gene regulation with IF 7.5. Here's when your paper fits, how it compares to Molecular Cell, EMBO Journal, and Development, and what editors reward.
Impact factor is a simple formula that gets complicated fast. Here's exactly what it measures, what it doesn't, and how researchers actually use it.
Nature and Cell are both top-tier for biology, but they want different things. Here's how to choose between them.
Author order disputes usually do not start with bad faith. They start with ambiguity. If the team never made the rules explicit, the paper becomes the place where status, labor, and credit all collide.
Desk rejection is not a side statistic. In many journals it is the main editorial filter. This report looks at the current Manusights journal dataset to show where that filter is harshest and what authors should infer from it.
Fast review times sound attractive until you realize that some of the fastest journals are simply fast at saying no. The slowest journals are not always inefficient either. In 2026, the extremes make sense once you read them as editorial systems rather than as isolated numbers.
Impact factor looks like a simple ratio, and in one sense it is. The confusion starts when authors assume the ratio is more objective, field-neutral, or paper-level than it actually is.
A lot of authors looked at JCR 2024 and thought journals themselves had suddenly changed. In many cases, the bigger change was how Clarivate organized rankings, counted visibility, and surfaced journals in the comparison set.
Top journals do not reject strong papers because they hate good science. They reject strong papers when the question is too narrow, the evidence is too thin, or the framing does not justify elite attention.
A strong abstract does not try to summarize every detail. It tells a busy editor, reviewer, or reader what the paper is about, what was done, what was found, and why it matters, without overselling.
A methods section does not exist to prove that you did something complicated. It exists to let a skeptical reader understand exactly what you did, why you did it, and whether the results can be trusted.
Journal metrics are useful when you know what they measure and dangerous when you assume they answer more than they do. The trick is not picking one winner, but understanding what each metric sees.
A rejection letter is rarely the end of a manuscript. In 2026, a lot of papers move through transfer networks, publisher families, and informal fallback routes before they finally get published. The useful question is not whether transfer exists. It is how much of your review work and momentum survives the move.
The internet answer to 'Are MDPI journals good?' is usually tribal. The useful answer is more conditional. MDPI is a legitimate major publisher, but journal quality inside the portfolio is uneven enough that authors should assess titles one by one.
People talk about Nature, Science, and Cell as if they are one prestige bucket. They are not. The metrics overlap, but the editorial personalities are genuinely different, and those differences matter more than one or two points of impact factor.
APCs are no longer a niche publishing detail. For many labs, they shape journal choice almost as much as scope or impact factor does. The useful question is not whether APCs are high, it is where they are high, why they differ, and what authors can still do about them.
Preprint servers are not interchangeable. The right choice depends on field norms, public-health risk, moderation, journal policy, and whether early visibility helps or harms your workflow.
Acceptance rate sounds like the cleanest statistic in journal publishing. It isn't. The number is often estimated, rarely standardized, and easy to misread without desk rejection, scope, and post-review context.
Salami slicing is not just publishing more than one paper from one project. It is splitting essentially the same research question into thin papers that mislead readers about originality, overlap, or independence.
Self-plagiarism is a messy label because it mixes at least three different problems: text recycling, duplicate publication, and undisclosed overlap. The details matter.
Most papers do not get in trouble because a statistician loves complexity. They get in trouble because the design, analysis, and reporting do not support the strength of the claims being made.
Acceptance is not the end of the publishing process. It is the handoff from editorial decision-making to production, licensing, proofing, and final release, which creates its own delays and mistakes.
JAMA and NEJM are both top-tier clinical journals, but they have different editorial personalities. Here's how to decide between them.
Open access policy is now a workflow problem, not a side note for the acknowledgments section. If you wait until acceptance to think about compliance, you often limit your journal options too late.
Desk rejection hurts, but it's not the end of your paper. About 40% of manuscripts get desk rejected at high-impact journals. Here's what to do in the next 2-4 weeks to turn this around.
Nature Genetics JIF 29.0 demands scale plus functional follow-up and ancestry diversity. 11-day median first decision. Comparison with Nature, Cell, AJHG, and Genome Research.
Science Advances reaches first decision in 6-12 weeks for papers that pass the desk. Here's how the AAAS academic editor model affects your timeline.
Scientific Reports has a 2024 JCR impact factor of 3.9 and a 5-year IF of 4.3. Ranked Q1 in Multidisciplinary Sciences, it publishes over 31,000 articles per year.
Cell Metabolism editors are screening for papers where metabolism is the central biological story, not a supporting character. A strong cover letter makes that metabolic focus obvious fast.
Gastroenterology requires AI disclosure in Methods under a dual AGA and Elsevier framework, prohibits AI authorship and AI-generated images, and expects clinical guideline content to remain human-generated.
Gut editors are screening for translational GI research with mechanistic teeth, not descriptive clinical observation. A strong cover letter makes that translational case obvious fast.
Immunity editors are screening for mechanistic immunology that changes field understanding. A strong cover letter makes that conceptual shift obvious fast.
Chemical Communications publishes 4-page chemistry Communications with 30-35% acceptance and fast 2-4 week review. Learn the format constraints and how ChemComm compares to Angewandte.
Pre-submission guide for European Heart Journal covering ESC editorial standards, desk-rejection triggers, and how EHJ compares to Circulation.
Pre-submission guide for Frontiers in Plant Science covering section fit, APCs, the collaborative review model, and editorial screening criteria.
Nature Immunology is commonly estimated to accept about 8-10% of submissions and desk-rejects 70-80%. This guide covers the fundamental discovery standard, mechanistic depth requirements, and how it compares to Immunity.
Nature Medicine is commonly estimated to accept about 7-9% of submissions and desk-rejects ~85%. This guide covers the translational research bar, what separates Nature Medicine from Nature and NEJM, and the cascade transfer pathway.
Renewable & Sustainable Energy Reviews is a review-only journal with IF 16.3 and Q1 ranking. This guide covers what readiness means for a synthesis article, how RSER compares to alternatives, and when it fits.
Science is commonly estimated to accept about ~7% of submissions and desk-rejects ~75% within 7-10 days. This guide covers what AAAS editors filter for, article type selection, and when Science is a better target than Nature.
JAMA requires detailed AI disclosure in Methods including tool name, version, and manufacturer, prohibits AI authorship, and applies the same policy across all 14 JAMA Network journals.
JAMA Oncology editors are screening for clinically important oncology evidence that can survive close methodological scrutiny. A strong cover letter makes both obvious fast.
The Lancet gives you 300 words. Most journals give you a full page. That constraint changes everything about how you write a cover letter, and most authors get it wrong by trying to compress a standard letter instead of writing a different kind of letter entirely.
Nano Letters editors are screening for physical insight at the nanoscale, not just strong characterization data. A strong cover letter makes that insight obvious fast.
PNAS impact factor is 9.1 (JCR 2024), down from 9.4 in 2023. CiteScore 21.5, SJR 3.414, and the long-term trend explained.
JAMA is for oncology papers with broad clinical or policy consequence across medicine. JAMA Oncology is for oncology papers whose main audience is still cancer care.
A practical Annals of Oncology process guide covering what happens after upload, what editors test first, and where oncology papers lose momentum.
Nature Medicine impact factor is 50.0, SJR 18.333. See the five-year JIF, rank, quartile, and what these numbers mean before you submit.
A revision decision is not just a label. It is the editor's shorthand for how much trust remains in the manuscript, how much work is expected, and how close the paper is to acceptance.
Nature journal impact factor is 48.5 in 2024 after the COVID-era spike normalized. Here is the trend, what drove the change, and what the number means for authors.
Nature Biotechnology impact factor is 41.7 (JCR 2024). Q1, rank 2/177 in Biotechnology. Five-year JIF 59.5. Acceptance rate, review time, and what editors want.
JCO JIF 41.9 is the ASCO flagship for practice-changing oncology. Here's when your paper fits, how it compares to Lancet Oncology, Annals of Oncology, and JAMA Oncology, and what the 15% acceptance rate really means.
Frontiers in Plant Science has 25+ specialty sections. The cover letter's main job is getting the paper routed correctly. Name the section, name the organism, state the finding.
Small has an IF of ~13, accepts 20-25% of submissions, and desk-rejects ~40%. This guide covers the nanoscience editorial bar, Communication vs Full Paper formats, and Small vs ACS Nano.
ACS Applied Materials & Interfaces requires demonstrated application data, not just material characterization. Learn the editorial bar, acceptance rate, and how to avoid desk rejection.
Nano Letters is commonly estimated to accept about 25-30% of submissions and emphasizes short-format reports of new nanoscale phenomena. This guide covers the editorial bar, Nano Letters vs ACS Nano, and common desk rejection triggers.
Blood requires AI disclosure in Methods under ASH rules, prohibits AI authorship and AI-generated images, and applies the same policy across Blood Advances and all ASH publications.
The BMJ requires AI disclosure in Methods and via its submission form, prohibits AI authorship and AI-generated images, and applies BMJ Publishing Group rules across all BMJ specialty journals.
Cancer Cell does not publish a strong official acceptance rate. The better submission question is whether the study delivers a mechanistic cancer biology advance with translational significance.
Cancer Research does not publish a strong official acceptance rate. The better submission question is whether the paper delivers a real mechanistic cancer advance for a broad AACR readership.
Cell Host & Microbe editors are screening for true host-microbe interaction logic. A strong cover letter makes that mechanism obvious fast.
Cell Metabolism often tells authors relatively quickly whether a paper belongs in a flagship metabolism journal, but the real submission question is mechanistic consequence, not just speed.
Clinical Cancer Research does not publish a strong official acceptance rate. The better submission question is whether the study bridges laboratory cancer science and clinical application at the AACR translational standard.
Clinical Infectious Diseases editors are screening for patient-management relevance, not just interesting pathogen data. A strong cover letter makes that consequence obvious fast.
European Heart Journal editors are screening for cardiovascular findings with broad clinical impact. A strong cover letter makes the ESC-flagship case obvious fast.
Applied Sciences is a legitimate MDPI journal, not a predatory one. The real decision is whether its broad, section-driven, high-volume model is the right fit for your work.
MDPI is not a clean fit for the word predatory, but it is also not a publisher authors should treat casually. The real question is journal-by-journal trust and strategic fit.
Advanced Materials desk-rejects 50-60% of submissions for insufficient novelty. Understand the IF 26.8 bar, visual quality expectations, and what 'advanced' really means editorially.
Applied Surface Science requires genuine surface science, not bulk materials with XPS data. Learn the 25-% acceptance25 rate, scope filter, and surface characterization expectations.
Astronomy & Astrophysics is commonly estimated to accept about 55-65% of submissions with no page charges. Learn the European astrophysics standard, ESA mission connections, and how A&A compares to ApJ and MNRAS.
Practical guide to Energy (Elsevier) submission standards, covering the systems-level framing editors require and common desk-rejection triggers.
Pre-submission guide for Food Chemistry covering analytical rigor expectations, novel chemistry requirements, and why nutrition-focused studies get desk-rejected.
Pre-submission guide for Gastroenterology covering the AGA editorial bar, desk-rejection patterns, and how to position GI research for acceptance.
Pre-submission guide for Gut covering translational GI research requirements, mechanistic depth expectations, and why descriptive studies fail review.
Pre-submission guide for JAFC covering scope fit, common rejection patterns, and how it compares with Food Chemistry.
Pre-submission guide for Journal of Power Sources covering battery and fuel-cell fit, benchmarking requirements, and what editors screen for.
MNRAS is commonly estimated to accept about 55-65% of submissions with no page charges. This guide covers what RAS editors screen for, MNRAS vs ApJ trade-offs, and when MNRAS is the better choice.
Nature Genetics is commonly estimated to accept about 8-10% of submissions and desk-rejects 75-80%. This guide covers what editors expect beyond GWAS associations, functional validation requirements, and the Nature cascade pathway.
Physical Review B publishes 7,000+ condensed matter papers yearly with ~50-55% acceptance. This guide covers what APS editors screen for, PRB vs PRL decisions, and common rejection patterns.
RSC Advances is commonly estimated to accept about 40-45% of submissions with fast 2-4 week reviews and a ~$1,800 APC. This guide covers when the RSC's broad OA journal is the right choice and when to aim higher.
Science Advances is commonly estimated to accept about 23-27% of submissions and desk-rejects ~50%. This guide covers cross-disciplinary framing requirements, the AAAS editorial bar, and how it differs from Science.
Sustainability (MDPI) is commonly estimated to accept about 40-50% of submissions with an IF of ~3.3 and a $2,400 APC. This guide covers MDPI scope, special-issue dynamics, and when the journal genuinely fits your work.
JCO limits Original Articles to 3,000 words with a structured abstract (Purpose, Methods, Results, Conclusion) and up to 5 display items. AMA-style superscript references and a mandatory Protocol Summary for clinical trials.
JI editors screen for whether the immunological question drives the paper. A cover letter that frames the work as disease biology with an immune component gets returned before review.
Lancet Oncology editors are screening for practice consequence with broader real-world relevance. A strong cover letter makes that wider oncology case obvious fast.
Molecular Cell does not publish a strong official acceptance rate. The better submission question is whether the study reveals a molecular mechanism with enough depth and novelty for the Cell Press flagship in molecular biology.
Molecular Cell editors are screening for mechanism, not just strong molecular data. A strong cover letter makes that mechanistic case obvious fast.
Nature Biotechnology editors are screening for enabling technology, not just strong biology done with modern tools. A strong cover letter makes that distinction obvious fast.
Nature formatting: advance with broad significance to the natural-sciences readership.
Nature Genetics does not publish a strong official acceptance rate. The better submission question is whether the study advances genetic understanding with broad significance and rigorous evidence.
Nature Immunology occupies a specific niche: broader than Immunity, narrower than Nature. Your cover letter needs to prove your paper advances fundamental understanding of the immune system, not just report something new happening in an immune context. That distinction determines whether you clear editorial triage.
Nature Medicine editors are screening for the bridge between mechanism and human-disease consequence. A strong cover letter makes that bridge obvious fast.
Nature Reviews Cancer does not publish a strong official acceptance rate. The better submission question is whether the topic and author team are realistic for a commissioned flagship review.
NRMCB operates almost entirely on a commissioned model. You submit a proposal, not a manuscript. The editors want authority, timeliness, and clear writing pitched to a broad molecular and cell biology audience.
Physical Review Letters charges ~$2,700 for open access (hybrid). SCOAP3 covers HEP articles free. APS pricing, institutional deals, and cost comparisons.
PLOS ONE formatting: PLOS ONE academic editors enforce reproducibility-first review.
PNAS formatting walkthrough for broad-significance contribution communic. Word limit, figure rules, references, reviewer-list.
How Science Advances editors enforce formatting on broad-impact methodological advance work. Word caps, figure formats, ref style, supplementary.
Format rules at Science for advance: abstract limits, supplementary policy, what desk-screen flags.
Sustainability (MDPI) format spec: sustainability research alignment, word/figure caps, reviewer expectations.
Trends in Molecular Medicine does not publish a strong official acceptance rate. The better submission question is whether a Cell Press editor would want this as a sharply argued review or opinion piece.
Our reviewers include researchers like this one who have published in and reviewed for top journals. Get a structured pre-submission review before you submit.